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Abstract—Over the past decade, there has been an unprece-
dented international focus on improved quality and availability of
medical care, which has reignited interest in clinical automation
and drawn researchers toward novel solutions in the field
of physiological closed-loop control systems (PCLCs). Today,
multidisciplinary groups of expert scientists, engineers, clini-
cians, mathematicians, and policy-makers are combining their
knowledge and experience to develop both the next generation
of PCLC-based medical equipment and a collaborative commer-
cial/academic infrastructure to support this rapidly expanding
frontier. In the following article, we provide a robust introduction
to the various aspects of this growing field motivated by the
recent and ongoing work supporting two leading technologies:
the artificial pancreas (AP) and automated anesthesia. Following
a brief high-level overview of the main concepts in automated
therapy and some relevant tools from systems and control theory,
we explore – separately – the developments, challenges, state-of-
the-art, and probable directions for AP and automated anesthesia
systems. We then close the review with a consideration of the
common lessons gleaned from these ventures and the implications
they present for future investigations and adjacent research.
Index Terms—Adaptive control, artificial intelligence, anes-
thesia, artificial pancreas, automated anesthesia, automation,
Bergman minimal model, BMM, blood glucose, closed-loop,
control, cyberphysical systems, decision-making, diabetes, drug
dosage, fuzzy-logic, fuzzy logic, F-L, general predictive con-
trol, GPC, IDDM, in-silico, insulin, medical cyberphysical sys-
tems, model predictive control, MPC, PCLC, pharmacody-
namics, pharmacokinetics, physiological systems, physiological
closed-loop control, physiology, PK-PD, prediction, Propofol,
proportional-integral-derivative, PID, remifentanil, systems phar-
macology, systems physiology, therapy, Type 1 diabetes, Type 2
diabetes, T1DM, T2DM
I. INTRODUCTION
The modern advance of automated and intelligent sys-
tems toward more-and-more visible roles in society (e.g.,
commercially available automated vehicles, humanoid and
biomimetic robots, household vacuums and thermostats, etc.)
has accelerated the development of many new technologies
and restored interest in several challenging fields. Principal
among these recent works, are the broad ongoing efforts to
deploy collaborative human-machine systems, such as those
designed to provide advanced support in medical diagnostics
and therapy. In this review, we focus on a special class
of these systems that apply concepts from feedback control
to attain automatic regulation of physiological variables –
such as blood pressure, depth of anesthesia, blood glucose
concentrations, and others (see examples in Table I) – known
as physiological closed-loop control systems (PCLCs). While
the pioneering works toward many kinds of PCLCs were
performed over a half-century ago, we are now only nascent in
an era of suitable computational/technological availability and
physiological/pharmaceutical scientific understanding to begin
realizing these devices on a broad commercial scale.
From the outset, it is important to understand that these
devices do not and are not intended to replace expert and
supporting clinical staff. In fact, automated devices rely on the
knowledge of experts and simply put, promise to do a much
better job at following clinical instruction than present technol-
ogy. By introducing sensors capable of continuous monitoring
(i.e., generating measurements every few seconds or minutes
depending on the treatment) these devices stand to recognize
and eliminate unintentional variations in therapies, including
missed doses and faults like sensor detachment or blocked
fluid pathways. Furthermore, post analysis of the measure-
ments obtained by these devices and the treatment profiles they
generate can provide important insights into the effectiveness
of treatment strategies (e.g., the clinical setpoint is maintained
to no effect), possible heterogeneity in disease pathologies, and
goals for future pharmaceuticals (e.g., short or longer acting
doses). The development and adoption of these new systems is
currently providing research directions in control engineering,
artificial intelligence, human-machine interactions, social sci-
ence, medical practice, therapeutic technology, pharmaceutical
development, and biological/physiological systems modeling.
Further, since poor controller performance in physiological
systems can lead to immediate adverse, potentially irreversible,
and even fatal physiological responses, PCLCs are a rapidly
developing field of safety critical control systems and addi-
tional research on safe PCLC operation will be of particular
value in the transition to common medical practice (esp. as
networked and ambulatory systems are realized).
As a primer for researchers in these and other disciplines,
we have sought in this review to introduce key information
from various aspects of the ongoing research to provide both
a background and up-to-date perception of the field for unfa-
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Fig. 1. Comparison of (a) manual therapy applied by a clinician according
to observations and set guidelines for making therapy adjustments and (b)
automated therapy applied by a physiological closed-loop control (PCLC)
device according to a control algorithm with the possibility of a clinician
acting in a supervisory capacity (e.g. monitoring Bispectral Index (BIS) for
additional safety in anesthesia).
miliar readers. This includes a brief introduction to modeling
and control, within the scope of those methods common to
physiological systems, in Section II; the use of case studies
in Sections III-IV to frame and discuss important topics in
current research; and a minimalist presentation of the detailed
mathematical models, which are all very well documented in
the cited references. Following the case studies, in Section V
we will discuss several aspects from these investigations that
are of great importance in the broader scope of physiological
control as well as possible directions for the future.
II. PRELIMINARIES
Regardless of the controlled variables and outputs, the
general process implemented in PCLCs can be represented
conceptually by a diagram resembling Fig. I. Here, a control
algorithm – normally implemented on a computer/processor
– provides an interface between (i) target values for phys-
iological variables that have been specified by clinicians,
(ii) feedback signals containing measurements and estimates
of system variables, and (iii) the infusion pumps or other
actuators that apply treatment to the patient. Notice, from
a high-level perspective, there is little difference between
the ”automated” approach and the classical manual approach
aside from the simplification of tasks required from the clin-
ician/patient, who no longer has to interact with the infusion
pump (or other actuator) directly and instead can focus on
specifying treatment goals and assessing therapy performance.
Recognizing the generality of this concept, many agencies
and organizations are in the process of developing more
rigorous guidelines for commercial PCLCs that will help to
establish the scope of this up-and-coming class of devices.
As noted in a recent paper from researchers at the Center for
Devices and Radiological Health (CDRH) at the US Food and
Drug Administration (FDA), the CDRH maintains a working
definition of PCLC medical devices (or PCLC devices) as, ”a
medical device that incorporates physiological sensor(s) for
automatic manipulation of a physiological variable through
actuation of therapy that is conventionally made by a clinician”
[9]. This definition – demonstrated in Fig. Ib – recognizes the
role of automation in PCLC while allowing a great deal of
flexibility in the disorder being treated, the types of sensors
and therapies used (many are certainly yet to be discovered),
and the extent to which the PCLC operates independent of
clinician intervention – known as the level of automation
(LOA) [9]. To help guide the development of commercial
PCLC devices, the United States [10], Canada [11], and the
European Union [12] have formally recognized versions of
the recently developed IEC 60601-1-10 consensus standard
[13], which is the first standard to provide, ”requirements for
the development (analysis, design, verification and validation)
of a physiologic closed-loop controller (PCLC) as part of a
physiologic closed-loop control system (PCLCS) in medical
electrical equipment and medical electrical systems to control
a physiologic variable” [13]. Beyond regulatory concerns, such
guidance may help the broader research and development
communities establish a common language (possibly even one
that is shared among medical and engineering professionals);
a set of safe design practices, testing procedures, and quality
management objectives; and a platform to qualify and address
issues raised by designers, clinicians, and patients.
Treating this feedback system similar to those in more tradi-
tional engineering disciplines, the design and implementation
of PCLCs requires accurate models of the patient, sensor, and
actuator dynamics, including any fundamental limitations and
safety constraints. While it may be obvious that the sensor
and actuator dynamics can be described using traditional dif-
ferential equations, similar mathematical modeling techniques
can also be applied to develop equations representing patient
physiology and pharmaceutical action. In fact, the human body
is generally modeled using compartmental techniques (see
Section II-A) from mathematical systems physiology, which
can describe the behavior of healthy and perturbed organ/tissue
interactions as well as the distribution/transportation of phar-
maceuticals in the body (pharmacokinetics) and the action of
these pharmaceuticals on certain organ systems (pharmacody-
namics) in terms of nonlinear differential equations.
A. Compartmental Models
When working with physiological or biological systems,
the dynamic interactions of system states/variables are often
depicted in the form of compartmental models. This represen-
tation is slightly different from the standard block diagram
models of systems theory but conveys similar information.
Under this modeling paradigm, a system is comprised of
one or more compartments, each of which has a (normally)
fixed volume Vi and contains a variable state quantity qi(t).
The representation of this quantity qi(t) as a fraction of the
compartment volume gives the concentration ci(t) = qi(t)/Vi
TABLE I
EXAMPLES OF RESEARCH IN PHYSIOLOGICAL CLOSED-LOOP SYSTEMS (PCLCS).
Treatment Target Treatment Actuator Treatment Sensor Control Method
Blood Glucose (e.g. [1]) Insulin infusion/bolus Blood GlucoseConcentration PID
Anesthesia (e.g., [2]) Propofol/Remifentanil Electroencephalogram/Bispectral Index Fuzzy-Logic
Blood Pressure (e.g., [3]) Vasoactive drugs suchas phenylephrine
Mean Arterial
Pressure
Linear Parameter
Varying Control
Anemia in End-stage-
Renal-Disease (e.g., [4])
Erythropoiesis-
stimulating agents Hemoglobin Level
Model Predictive
Control
Tumor Growth (e.g., [5]) Abiraterone Tumor Composition EvolutionaryGame Theory
Heart Failure (e.g., [6], [7]) Implantable RotaryBlood Pump
Left Ventricle Pressure
/Flow Pulsatility
Sliding Mode
Control
Fluid Resuscitation (e.g., [8])
Intravenous fluid
administration (IV injection
of replacement fluids/blood)
Stroke Volume; Heart Rate;
Mean Arterial Pressure;
Pulse-Pressure Variation
Predictive Rule-
Based Control
𝑘02
𝑘12
𝑉2, 𝑞2 𝑡𝑉1, 𝑞1 𝑡
𝑘21
𝑘01
𝑢1 𝑡 𝑢2 𝑡
Compartment 2Compartment 1
Fig. 2. General compartmental model for 2 compartment systems
. When the change in these quantities or concentrations takes
the form of ordinary differential equations, a compartmental
modeling diagram can be drawn to depict the contributions of
each state quantity to the dynamics (similar to state-variable
representation). In the case of a linear time-invariant system,
every compartment is associated with a linear first order
differential equation described by the signals entering and
leaving the respective compartment. Considering the general
two-compartment model shown in Fig. 2, the change in q1(t)
is given by
q˙1(t) = u1(t)− k21q1(t) + k12q2(t)− k01q1(t) (1)
where u1(t) is the input to compartment 1; k01q1(t) is the
leakage from this compartment to the environment; k21q1(t)
is the exchange from compartment 1 to compartment 2; and
k12q2(t) is the exchange from compartment 2 to compartment
1. Similarly, based on the arrows pointing toward and away
from compartment 2, the change in q2(t) can be written as
q˙2(t) = u2(t) + k21q1(t)− k12q2(t)− k02q2(t) (2)
where u2(t) is the input to compartment 2; k02q2(t) is the
leakage/loss from compartment 2 to the environment; and all
other terms are the same as described previously.
Together, these equations describe the exchange between
compartments and the environment. In general, there may
be n compartments, each of which may have a constant or
changing volume Vi and can be linked to any or all other
compartments by linear or nonlinear interactions. For more
detailed information on compartmental modeling, readers are
referred to the extensive coverage in [14].
B. Control Methodologies
In this section, we briefly review the fundamentals of the 3
most common control methods currently used in physiological
systems: (i) proportional-integral-derivative (PID) control, (ii)
model predictive control (MPC), and (iii) fuzzy-logic (F-L)
control. The application of these control schemes to specific
physiological systems, including the advantages, variations,
and recent developments to each strategy, are described in later
sections. Of course, many other control methods are also being
pursued in the literature and will be discussed as needed.
1) Proportional-Integral-Derivative (PID) Control: PID
control is one of the most frequently used control approaches
in industrial systems due to its simple mathematics, well-
known gain tuning methods, and broad application to both
linear and nonlinear systems. The Laplace domain transfer
function of the ideal PID controller can be given by
U(s)
E(s)
= kp
(
1 +
1
sTi
+ Tds
)
(3)
where s is the complex-valued Laplace variable; E(s) and
U(s) are, respectively, the Laplace domain input and output
of the PID controller; kp is the proportional gain; Ti is the
integral time-constant; and Td is the derivative time-constant.
In most cases, the coefficients kp, Ti, and Td are free-
parameters that take constant values and are designed to obtain
desirable system properties. The values of these parameters
may be obtained by either theory-based design strategies or
numerical/experimental tuning methods.
2) Model Predictive Control (MPC): Model predictive con-
trol is a robust and optimal control technique used to handle
systems with constraints while optimizing the controller action
and predicting system outputs for robustness against noise and
Fig. 3. Fuzzy logic sets
disturbances. The basic formulation of this controller can be
given by
U∗t (x (t)) := argmin
N−1∑
k=0
q (xt+k, ut+k) (4)
subject to
xt = x(t) (Measurement or estimation)
x(t+k+1) = Ax(t+k) +Bu(t+k) (System model)
x(t+k) ∈ χ (State constraints)
u(t+k) ∈ u (Input constraints)
U∗t (x(t)) = {u∗t , u∗(t+1), , u∗(t+N−1)}(Optimization variables)
where U∗t (x(t)) is the optimal input sequence for the entire
planning window N ; q is the cost function; and χ and u
are, respectively, sets of state and input constraints. At any
given time t, this controller finds the set of optimal control
actions U∗t based on the predicted dynamics over the entire
window N and implements only the first control action u∗t in
this sequence.
3) Fuzzy-Logic (F-L) Control: Fuzzy systems are
knowledge-based or rule-based systems consisting of fuzzy
”if-then” rules that represent heuristic verbal conditions as
continuous membership functions Fig. 3 [15]. This method
can be used to model and control complex dynamics,
nonlinear systems, and systems that are difficult to express
mathematically. In general, fuzzy-logic systems can be
classified as Mamdani and Sugeno systems [16]–[18]. Fuzzy-
logic systems have been successfully implemented in many
industries.
C. Case Studies
In order to demonstrate and contextualize many important
principles in PCLCs, we will proceed over Sections III and
IV with detailed case studies of the two most active areas
in physiological control: (i) automated anesthesia and (ii)
automated insulin therapy for diabetes. For each system, a
detailed background on therapeutic goals, physiology, and
mathematical representations is given prior to discussions
on current trends in the control methodologies and specific
challenges encountered in each area.
III. DIABETES AND THE ARTIFICIAL PANCREAS
To understand the problem of blood glucose regulation,
let us begin with a brief review of the essential physiology
of a properly functioning glucoregulatory system and build
towards a fundamental understanding of the diabetic disorders
(pathophysiology) as well as their underlying causes (etiology)
and associated health risks (complications and comorbidities).
By way of this introduction, we hope to provide clarity for
the coming discussions on system models and insights when
broaching the subjects of treatment and closed-loop therapy.
A. Physiology of the Healthy Blood Glucose Regulatory Sys-
tem
The natural regulation of blood glucose in a healthy in-
dividual is the result of a variety of interacting physiological
processes involving hormones, neurotransmitters, and our own
consumption of food. Historically, the accepted metric for
judging the quality of this regulation is the amount of glucose
present in the blood stream, measured as a molar (mmol/L) or
mass (mg/dL) concentration. This blood glucose concentration
is commonly referred to as an individual’s blood glucose level
and is generally well-maintained between about 4-6 mmol/L
(72-108 mg/dL) during healthy glucose homeostasis. However,
even in healthy subjects, there are occasional excursions above
this range (e.g., after recent meals) or slightly below it (e.g.,
during or after periods of high activity). The interactions that
govern glucose concentrations are highly diverse and most, if
not all, of these interactions are reciprocal – both the glucose
concentration and the acting processes are mutually affected
by the regulatory procedure. The systems involved in this
regulation include the brain, liver, kidney, gastrointestinal tract,
adipose and muscle tissues, and pancreas. Of these systems,
the pancreas is arguably the most critical for maintaining
proper blood glucose and will be our focus in the sequel.
The pancreas, located behind the stomach, is a glandular
organ primarily responsible for secreting digestive enzymes
through ducts to the small intestines and releasing pancreatic
hormones into the blood stream. While both enzymes and hor-
mones play important roles in proper metabolic homeostasis,
it is the latter (i.e., hormones) that are principally responsible
for regulating blood glucose levels [19].
These hormones, known as the pancreatic hormones, are
produced at small clusters of endocrine cells (i.e., cells that
secrete directly into the blood stream), known as islets, that
are distributed sparsely throughout the pancreatic tissue (com-
prising <2%). These pancreatic islets (or islets of Langerhans)
are constructed from a combination of 5 kinds of endocrine
cells called α-cells, β-cells, γ-cells, δ-cells, and -cells. Each
of these cell types secrete a specific set of hormones that are
known to be involved in at least some aspects of normal glu-
coregulatory function. Of these cells, the α and β types make-
up >80% of all pancreatic islet cells and are considered the
2 most essential endocrine cells for blood glucose regulation
[19]. The first of these, α-cells, produce a single hormone
called glucagon, which drives the production of endogenous
glucose by catabolizing (breaking-down) stored glycogen in
the liver (known as hepatic glycogenolysis) and to a lesser
extent by promoting the generation of glucose from non-
carbohydrate compounds in the liver and kidneys through pro-
cesses termed, respectively, hepatic and renal gluconeogenesis.
The latter type of cells, β-cells, produce 3 hormones called
C-peptide, amylin, and insulin, all of which have important
roles in glucose regulation and are believed to correspond with
various symptoms of blood glucose pathophysiology. Of these
3 hormones, insulin is the most well-known, and is responsible
for lowering blood glucose concentrations through promotion
of glucose utilization by adipose and muscle tissues, as well
as by prompting the creation of glycogen and fatty acid energy
stores from glucose through glycogenesis and lipogenesis,
respectively. Thus, in contrast to glucagon, which raises blood
glucose levels, insulin provides the primary means to reduce
this concentration [19].
As one might expect, based on their roles in the blood
glucose regulatory function, glucagon is primarily secreted
during periods of low blood glucose such as sleep or fasting,
while insulin secretion is stimulated by elevated blood glucose
concentrations and the incretion effect promoted by ingestion
of glucose, fructose, amino acids, and long-chain free fatty
acids [19]. Of course, insulin secretion is highest following
meals (i.e., when blood glucose levels are at their highest).
Together, glucagon and insulin provide the basis for many
simple and intuitive bi-hormonal models of the pancreatic
endocrine system. While many of the physio-chemical mech-
anisms for these secretions and uptakes are quite well known,
it is important to understand that these hormones are released
directly into blood stream and interact with many different
organ systems. Thus, the specific mechanisms and outcomes
of these interactions remain highly active research topics.
Of course, the 2 other β-cell hormones and those secreted
from the γ, δ, and -cells are also intrinsic to proper phys-
iology. Unfortunately, the functions of these hormones are
not yet as well understood as those of insulin and glucagon
and are often (perhaps necessarily) disregarded in the control-
oriented literature. However, there is reason to believe study of
these pancreatic hormones, and their roles in both physiology
and pathophysiology, will likely lead to better multi-hormonal
models and treatment approaches in the coming years [19],
[20]. For example, amylin – produced by β-cells along with
insulin – is believed to perform complementary functions
to the insulin-based removal of glucose, instead inhibiting
the appearance of absorbed (exogenous) and glycogenolytic
glucose by, respectively, reducing the flow of food from
the stomach to the small intestines (gastric emptying) and
blocking the release of postprandial glucagon (i.e., inhibiting
unnecessary endogenous glucose secretion following meals)
[20]. While an FDA-approved amylin analog (i.e., pramlintide)
is available, the cost of treatment with such complimentary
hormone analogs may be prohibitively expensive and perhaps
even detrimental if not properly (e.g., physiologically or
pseudo-physiologically) controlled.
1) Pathophysiology and Etiology: Type 1 Diabetes Mellitus
(T1DM): The term type 1 diabetes mellitus describes blood
glucose regulatory disorders resulting from the complete (or
near complete) destruction of all pancreatic β-cells, leading to
hyperglycemia and life-threatening complications. T1DM is
generally caused by an auto-immune response, but does occur
infrequently without any known or identified cause (idiopathic
T1DM) [21], [22]. The characteristic β-cell destruction of
T1DM leads to a dependence on external sources of insulin
(i.e., insulin therapy) for survival; hence, this form (esp. the
auto-immune form) was previously identified by the term
insulin-dependent diabetes mellitus (IDDM) [21], [23]. Type
1 diabetes accounts for 5-10% of all cases [21].
Considering the preceding discussions on healthy
glucoregulatory function, it is clear that destruction of
β-cells in T1DM suppresses the production of the insulin,
amylin, and C-peptide hormones. Without these hormones
(particularly insulin), cells throughout the body cannot remove
glucose from the blood stream for use in metabolic processes
(e.g., storage as glycogen). As a result, the body turns toward
the metabolism of fats, which leads to increased levels of
free fatty acids and ultimately ketones in the blood stream
[23]. Overproduction of the latter leads to life-threatening
diabetic ketoacidosis. Furthermore, complications due to
elevated blood glucose levels (hyperglycemia) appear across
numerous organ systems and include microvascular diseases
such as neuropathy, retinopathy, and nephropathy [23], [24].
In T1DM, the absence of interactions between pancreatic
α-cells and β-cells removes an important pathway for natural
glucagon regulation, leading to continued glucagon production
during periods of elevated blood glucose, resulting in more
severe hyperglycemia and even greater risk of complications
[23]. Unfortunately, while many of the risks associated
with T1DM can be reduced by tight regulation of blood
glucose levels [23], the destruction of β-cells affects multiple
hormones and many systems, some of which are not fully
restored by external blood glucose regulation. For instance,
increased risk of cardiovascular disease – the leading cause
of reduced life-expectancy in type 1 diabetics – remains
prevalent in type 1 diabetics with good blood glucose control
[23].
Type 2 Diabetes Mellitus (T2DM): The term type 2 dia-
betes mellitus describes a family of blood glucose regulatory
disorders that are marked by relative insulin deficiency, due
to a combination of poor insulin production and poor insulin
utilization, leading to episodes of hyperglycemia [21], [22].
Previously identified as non-insulin-dependent diabetes melli-
tus (NIDDM), current opinion is trending towards a more grad-
uated classification system that may improve differentiation of
T2DM by severity and pathophysiology of impaired insulin-
secretion (production) and insulin-sensitivity (utilization) [21],
[25], [26]. Type 2 diabetes accounts for about 85% of all cases
[21], [23], [26].
Unlike T1DM, T2DM is not an autoimmune disorder
and has neither a single underlying cause (etiology) nor a
unique physical origin. Instead, the term T2DM applies to
various non-specific disorders (i.e., not specifically meeting
the criteria for definition as any distinct disorder such as
monogenic, gestational, or type 1 diabetes mellitus) that
result in chronic excess blood glucose [21], [22]. While
in some cases, T2DM is marked by a reduced pancreatic
insulin secretion that results in a relative insulin deficiency, in
others, insulin production is unaffected, but cells exhibit an
inability to utilize available insulin (i.e., insulin resistance).
However, most of the type 2 diabetic population exhibit
both insulin deficiency and insulin resistance [21], [22], [25],
[26]. Thus, it is becoming more common to characterize
each instance of T2DM along gradients of insulin-sensitivity
and insulin secretion (among other variables including
coexisting conditions), to better identify root-causes and
optimal treatment regimens [25], [26]. While T2DM is
not normally life-threatening by itself, it is associated with
reduced life-expectancy due to macrovascular complications,
as well as numerous microvascular complications that are
believed to be linked with episodes of hyperglycemia. Like
T2DM itself, the accompanying complications are diverse
and, some research suggests, potentially well-correlated with
pathophysiologically distinct forms of the disorder [25]–[27].
Gestational Diabetes Mellitus (GDM): Glucose intolerance
that develops in women during pregnancy, indicated by
the emergence of persistent hyperglycemia, is known as
gestational diabetes mellitus [21], [22], [28]. Like T2DM,
GDM is comprised of a highly heterogeneous set of disorders,
which may present predominantly insulin resistant or insulin
deficient characteristics [28]. While standards for diagnosing
GDM vary, the critical feature of GDM is that it is developed
during pregnancy and was not present prior [21]. The
pathophysiology of GDM is not yet well-understood [28], but
ongoing research may benefit from more accurate and detailed
sensing technologies. GDM is a disorder of international
interest and can result in complications for both mother and
child and can progress into a form of T2DM after pregnancy
[21].
Other Specific Types of Diabetes: In addition to T1DM,
T2DM, and GDM, there are numerous, less common dia-
betic disorders (together comprising ¡5% of cases) with more
specific association with distinct etiological factors such as
genetics, drug or chemical exposure, and pancreatic diseases
[21], [22]. Differentiation of these specific forms from T1DM
and T2DM is critical, as the treatment requirements for
many of these disorders differ from general guidelines and
mischaracterization can lead to poor or detrimental outcomes
and unnecessary expenses [21], [25].
B. Traditional Monitoring and Treatment
Considering the variety of disorders that may exist, or
coexist, in diabetic individuals, it is not surprising that there
are a plethora of diabetic diagnostic tools and interventions,
some of which have been shown to be most effective in mon-
itoring and treating specific disorders, while simultaneously
potentially detrimental for treating others. Likewise, treatment
guidelines are often adjusted for improved effectiveness in
specific demographics often based on age, gender, and overall
health, with the final recommendation for individuals tailored
by their physician [29], [30].
1) Laboratory Screening: For the past half century, blood
glucose regulatory function and concentration targets for di-
abetics and non-diabetics have primarily been specified ac-
cording to 2 standard measurements: (i) static blood glucose
concentrations and (ii) percent glycated hemoglobin (HbA1c,
or less formally A1C). While a static measurement of blood
glucose provides insight into the current glycemic state (i.e.,
the current mmol/L concentration of glucose in the blood
stream), it does not provide any insight into recent concen-
trations or an indication of whether this value is increasing
or decreasing [31]. Conversely, A1C provides an approximate
indication of the average blood glucose concentration over a
period of about the preceding 2-3 months [29], [31]. While
A1C is less sensitive to daily blood glucose variations and a
primary predictor of diabetes related complications, acceptable
A1C values have been shown to vary significantly across pop-
ulations and with various environmental factors, and further
do not provide any specific information regarding occurrences
of hypoglycemia, hyperglycemia, or their severity [21], [29].
In clinical settings, diabetic screening is often performed
using plasma blood glucose concentrations that are measured
by accredited laboratories using standardized tests [32] to de-
termine levels under the moderately controlled circumstances
either following a period of fasting to obtain the so-called
fasting plasma glucose (FPG) level or 1-2 hours into an oral
glucose tolerance test (OGTT) administered after a period
of fasting. If the FPG or OGTT results fall below certain
thresholds (see characteristic thresholds from the ADA [21]
in Table II), these tests results, respectively, indicate impaired
fasting glucose (IFG) or impaired glucose tolerance (IGT)
associated with metabolic disfunction. The accuracy of these
tests depends heavily on patient adherence to the fasting
guidelines and clinical sample handling. Thus, for clinical A1C
(also performed in laboratories [32]), FPG, and OGTT testing,
confirmation of an initial diagnosis of diabetes often requires
that 2 of these values fall outside the acceptable thresholds
[21].
2) Self-Monitoring of Blood Glucose (i.e., ”Finger-Stick”
Monitoring): Once diagnosed, most diabetics (especially those
with T1DM or T2DM requiring insulin therapy) will re-
quire portable diagnostic equipment so that blood glucose
concentrations can be monitored according to the severity
of their disorders or in the event of symptoms that indicate
excursions from normal glycemic control. For many years, the
predominant method for this daily testing was self-monitoring
of blood glucose (SMBG) by so-called ”finger-stick” devices
[31], [33], which require drawing a small sample of blood
during every test. Initially accepted for their marked improve-
ment over urine testing equipment, use of these finger-stick
devices causes pain, and measurements can be uncomfortable
or unsafe (due to blood spill) to perform in public [31]. While
significantly less accurate than accredited laboratory testing
[32], these portable diagnostic tools have enabled diabetics
to maintain tighter glycemic control by regular assessment of
their blood glucose levels, especially prior to meals, sleep, and
insulin dosing. However, like static laboratory measurements,
TABLE II
FPG, OGTT, AND A1C THRESHOLDS FOR INITIAL DIAGNOSIS OF DIABETES.
Test Prediabetes Thresholds Diabetes Threshold
FPG 100-125 mg/dL (5.6-6.9 mmol/L) ≥126 mg/dL (7.0 mmol/L)
75-g OGTT (2 hour) 140-199 mg/dL (7.8-11.0 mmol/L) ≥200 mg/dL (11.1 mmol/L)
A1C 5.7-6.4% (39-47 mmol/mol) ≥6.5% (48 mmol/mol)
SMBG does not provide any historical or predictive informa-
tion by itself and must be combined with knowledge of recent
past/future carbohydrate intake, exercise, and medication dos-
ing to estimate appropriate corrective actions. Coupled with
the inconvenience and limitations of regular blood sampling,
the static nature of SMBG has prompted the modern quest
for safe, accurate, and continuous blood glucose monitors
(CGMs).
3) Continuous and Flash Glucose Monitors: Starting in the
late 1990s, diagnostic tools for continuous home monitoring
of blood glucose began to emerge as a potential remedy to the
shortcomings of traditional SMBG [31]. Originally designed
to record, but not display, blood glucose measurements over
several days – to be analyzed retrospectively by a physician
[32]–[34]– more recent real-time CGM (rtCGM) devices that
log data and provide immediate access to measurements and
analytical trends are now available on a broad commercial
scale (Table III) [31]. Unlike SMBG, which requires taking
blood samples at each measurement time, most rtCGM devices
are minimally invasive and measure glucose concentrations
subcutaneously through the interstitial fluid rather than whole
blood or plasma [32], [34]. These sensors can be worn
continuously for up to a week, and provide updated measure-
ments every 5 minutes, requiring finger-stick measurements
for calibration (up to twice per day) [32]. While only one
such device is FDA approved for non-adjunctive use in insulin
therapy (i.e., for use in determining insulin dosage without the
need to confirm blood glucose levels by traditional SMBG),
this is a recent development and more devices may be expected
in the future [29].
This consistent availability of current data has led to several
important features that are impossible with traditional SMBG.
First, many rtCGM systems allow users to set alarms that
indicate or even predict the onset of hypoglycemia, allowing
diabetics to increase their carbohydrate/glucose intake and
avoid hypoglycemia, which is especially useful for those
suffering from hypoglycemia unawareness [31]. Second, many
rtCGM systems allow users to automatically share data/trends
with caregivers and physicians, having important implications
for young children and their parents [31], as well as elderly
and disabled individuals who are living alone. Finally, rtCGM
systems not only provide improved predictive measures for
users through real-time measurements, measurement histories,
and predicted glycemic trajectories, many of these systems can
be interfaced with portable insulin infusion systems to auto-
matically suspend insulin dosing when near or approaching
hypoglycemia [31], [34]. Combinations of rtCGM and insulin
infusion systems, known as sensor augmented pump (SAP)
therapy, are further enabling improved overnight glycemic
control, and represent a step toward wide-spread acceptance
of closed-loop insulin therapy systems.
More recently, a new class of glucose monitor known
as the ”flash” or ”intermittently sensed” glucose monitor
(isCGM) have become available that provide immediate, on
demand glucose measurements (lagging true blood glucose
concentrations by about 5 minutes) in a minimally invasive
package worn continuously for 14 days without calibration
(the sensing element is replaced after 14 days without re-
quiring any SMBG calibrations) [33], [34]. While this device
may not be suitable for those with hypoglycemic unawareness
(developed by repeated hypoglycemic excursions) as it does
not currently provide an autonomous alert, various studies have
demonstrated improved time-in-range and greatly reduced time
in hypoglycemia in both type 1 and type 2 hypoglycemic
aware populations previously using finger-stick SMBG. Small
observational studies indicate that these results may follow
from the rapid and pain-free nature of blood glucose self-
monitoring with these devices, which allows users to follow
even stringent (¿10 times per day) testing guidelines without
experiencing discomfort [33]. This research has also reported
behavioral changes in patients, including better adherence to
monitoring timelines, which may produce additional societal
benefits, as unchecked low blood sugar is associated with
otherwise avoidable injuries and a increased risk of car ac-
cidents [42]. Due to time lag and measurement inaccuracy
– possibly exceeding 15% mean absolute relative difference
(MARD) from matched reference measurements – users of
these devices must still perform traditional SMBG tests when
hypoglycemia is expected, measurements vary rapidly or do
not corroborate symptoms, and when required by law [33].
While these flash monitors are available and gaining significant
interest, there remain significant concerns in areas including
sensor placement, failure modes, user insulin stacking due to
time lags, and measurement variations over the duration of the
14-day sensor life-span.
Studies on CGM devices have consistently indicated that,
compared to control groups using SMBG, insulin treated
diabetics using CGM systems show improved HbA1c as
well as significantly decreased frequency and severity of
hypoglycemia and hyperglycemia, with rtCGM demonstrating
superior outcomes to isCGM [29], [31], [33], [34]. Despite
their benefits, modern CGM sensors suffer from delays due to
glucose transport from plasma to the interstitial fluid, may be
subject to sensor interference from mechanical [43] and phar-
maceutical (e.g., acetaminophen [44]) sources, and are known
to demonstrate reduced accuracy during the first day of use
TABLE III
EXAMPLES OF COMMERCIALLY AVAILABLE CGM COMPONENTS AND DEVICE [31], [35]–[41].
Manufacturer Device Accuracy (MARD %) Duration RequiredCalibration
Medtronic Enlite Sensor* - 6 days -
Enlite with Gaurdian
2 link transmitter 11 6 days 2/day
Enlite with MiniLink
transmitter 13.6 6 days 2/day
Enlite with Guardian
connect transmitter 11 6 days 2/day
Guardian Sensor 3* - 7 days -
Guardian Sensor 3
with Guardian link 3
transmitter
10.6 7 days 2/day
Guardian connect
system
10.6 (abdomen)
9.0 (arm) 7 days 2/day
Dexcom G4 13 7 days 2/day
G5 9 7 days 2/day
G6 9.8 10 days none
Abbot FreeStyle Libre 11.4 14 days none
*Sensing elements may limit the duration CGM systems and affect their accuracy but do not alone give
the mean absolute relative difference (MARD) or calibration schedule.
and at low glucose concentrations (i.e., near hypoglycemia)
[31], [43]. With further research, these issues may be resolved
in the near future.
4) Non-Invasive, Wearable, and Implantable Monitoring:
During the past decade, there has been increased academic
and commercial interest in the development of non-invasive
and continuous monitoring of blood glucose levels through
wearable technologies. Unlike traditional monitors, many of
these sensors do not measure blood glucose directly, but at-
tempt to leverage alternative fluids such as urine, sweat, saliva,
breath, ocular fluid, and interstitial fluid [45]. While some of
these devices are promising, with many designed to be discrete
and comfortable, measurements taken from these alternative
physiological fluids tend to be less reliable than traditional
methods, and any such technology will surely require rigorous
testing and clinical studies before any statements can be made
regarding safety and accuracy [46].
5) Non-Insulin Therapy: While not generally suitable for
T1DM, non-insulin oral antihyperglycemic agents are com-
mon in treating T2DM. In fact, the first-line pharmaceuti-
cal therapy for T2DM is a non-insulin antihyperglycemic
called metformin, which reduces hepatic glucose production
(i.e., in the liver) and is often highly effective at reducing
HbA1c and associated cardiovascular risks, without raising
significant concerns of hypoglycemia [30]. According to ADA
guidelines, metformin is frequently prescribed as part of a
dual or triple pharmaceutical regimen (combination therapy)
when metformin alone does not provide sufficient reductions
in HbA1c – used in this case as a primary indicator of
glycemic control. These additional treatments may be oral
agents such as sulfonylureas (increases insulin secretion),
DPP-4 inhibitors (increases glucose dependent insulin secre-
tion and decreases glucose dependent glucagon secretion), and
Thiazolidinediones (increases insulin sensitivity), but may also
include subcutaneous injections of insulin or GLP-1 receptor
agonists, which act on multiple levels [30].
Considering the underlying lifestyle factors (e.g., sedentary
behavior, obesity, and diets that are high in fats and sugars
[47]) that are known to promote the development of T2DM,
prevention and treatment through lifestyle modification is a
significant area of study [47]–[49]. Intensive lifestyle modifi-
cations have been shown to improve HbA1c, and are believed
to be associated with reduced microcardiovascular and macro-
cardiovascular complications as well as lower rates of diabetes
related mortality in T2DM. Similarly, there is evidence to
support the benefits of nutritional balance in T1DM; however,
the direct evidence for reduction of diabetes related ailments
(beyond general health and fitness) associated with physical
activity and obesity are much better supported for T2DM. In
fact, due to the increased glycemic variability of individuals
with T1DM, the ADA recommends physicians take care in
prescribing specific exercises and durations for individuals
when using physical activity as a means of glycemic control
[49].
While these non-insulin therapies are often effective at
slowing the progression of T2DM, in some cases leading
to remission of the disorder, most individuals with T2DM
will often require insulin therapy at later stages of treatment,
even with careful adherence to therapy guidelines and healthy
lifestyle choices [30].
6) Multiple Daily Insulin Injections: Recalling that severe
insulin deficiency is the hallmark of T1DM related β-cell
destruction, it is not surprising that primary treatment for
T1DM is insulin therapy [30]. The most common method
of insulin therapy consists of the regular periodic injection
of basal (baseline) insulin multiple times a day – known
as multiple daily insulin injections (MDI)– supported by
additional insulin doses (boluses) and oral glucose or glucagon
as needed to maintain normoglycemic conditions (e.g., at meal
times). While several different practical guidelines exist for
calculating the required basal and bolus insulin doses, dosage
is always described in terms of units of insulin or units/day
(based on weight as units/kg/day).
Recent pharmaceutical advances have produced a variety of
injectable insulins that may be categorized as either synthetic
human insulin or modified insulin analogs. Referring to Table
IV [30], [50], variations in these insulin formulations have
led to markedly different properties, and so it is common to
classify insulins according to their concentration in units/mL
(e.g., an insulin specified as U-# contains # units/mL), the time
it takes for the insulin to begin reducing blood glucose levels
(onset time), the time it takes for the insulin action to reach
its peak effectiveness (peak time), and the length of time that
the formulation will remain effective after injection (duration)
[50]. When prescribing or taking insulin, each of these factors
comes into play and (in an MDI scheme) make some forms
better suited as basal insulin and others as mealtime boluses
[30]. Thus, even within insulin therapy, there is now an
array of options that allow for personalization and situational
evaluation of treatments.
Note, the use of insulin is not limited to T1DM, and there
are, of course, many factors affecting the selection, efficacy,
and safety of different insulin formulations and treatment
regimens. In addition to single insulin formulations, some
injections are developed as a mix of rapid acting (i.e., quick
onset and peak times with short duration) and long acting (i.e.,
delayed onset time, low or no peak, and long duration) insulins
to provide both basal and bolus action from a single injection,
thereby reducing the number of injections required per day
[30], [50].
In some cases, an analog of the pancreatic β-cell hormone
amylin may be used to augment insulin therapy [30]. However,
addition of such agents may increase treatment costs signifi-
cantly. Further, in certain cases, it may be beneficial to perform
pancreas or islet transplantation, in place of insulin therapy.
7) Continuous Subcutaneous Insulin Infusion: Initially de-
veloped over 40 years ago [51], continuous subcutaneous
insulin infusion (CSII) systems are portable pump therapy
devices that are generally constructed as a combination of
an onboard insulin reservoir, an electromechanical infusion
pump, and an infusion apparatus (tubing and cannula) [51],
[52]. According to various studies, these systems can be
operated using synthetic human insulin or rapid-acting insulin
analogs (RAIA), with RAIA providing superior performance
to synthetic human insulin [52]. In most cases, CSII uses
the same basal dosage as MDI, with the basal insulin dosage
applied more consistently over the day in CSII [52].
While pragmatic evidence supporting substantial improve-
ments to patient outcomes achieved by switch from MDI to
CSII is minimal or frequently contradicted [30], [52], there is
evidence that switching to CSII is beneficial for diabetics with
poor glycemic control under MDI [52], and CSII is beginning
to see adoption as a recommended first-line therapy for some
type 1 populations (e.g., adolescents) [30], [52]. However,
when CSII is used in conjunction with rtCGM for sensor
augmented pump therapy, the benefits are more pronounced.
Connected systems of monitoring and treatment devices, like
SAP, provide therapeutic opportunities that cannot be obtained
using MDI, such as overnight glycemic regulation. As an
extension of this concept, the ability to continuously monitor
and control insulin concentrations (whether by CSII or other
novel future technology) is paramount to the development of
closed-loop insulin therapies. Like SAP, closed-loop therapy
systems are designed to utilize the features of continuous
infusion that cannot be matched by MDI, with or without
CGM, to achieve tighter glycemic control than is possible by
any current treatment.
As with all therapy devices, CSII must be appropriately
used and maintained, as device performance depends on proper
operation (e.g., timely replacement of consumables) to avoid
failure modes such as clogged or impeded infusion pathways,
which can lead to insulin deficiency and hyperglycemia [52].
C. Modeling for Analysis and Control of Diabetes
Building on nearly 2 centuries of research and modeling
studies focused on the pancreatic endocrine system, the re-
cent worldwide interest in diabetes has instigated a surge in
the development of glucoregulatory models and simulation
platforms, primarily aimed at T1DM [53]–[57] and, to a
lesser extent, T2DM [54], [56], [57]. In fact, according to
several reviews [53], [57], there are well over 100 different
mathematical models describing, reproducing, and/or predict-
ing various aspects of the blood glucose regulatory dynamics
from cellular mechanisms and neurological signaling to long-
term outcomes, disease progression, and risks of complications
[57]. The mathematical descriptions used in these dynamic
models are diverse and include ordinary, partial, and stochastic
differential equations, which often include time-delays, and
are frequently treated with a degree of modularity – as new
models may be established as composites of subsystems from
multiple predecessors [57].
Among these models, some, such as the mechanistic models
that describe the Ca2+ and K+ ion channel mediated release
of insulin from pancreatic β-cells, have solid footing in the
first principles of electrochemistry and physics. However, the
inclusion off such models tends to add unwarranted complexity
as the pathophysiological and etiological relevance of these
states are not well-understood, while producing negligible
variations in the observable input-output behaviors that are
presently more relevant to healthcare outcomes. Thus, in the
development and analysis of systems for the closed-loop treat-
ment of diabetes, models are generally categorized according
to their level of detail and may be considered as either (i)
reduced complexity control-oriented models – for controller
synthesis methods [53], or (ii) high-fidelity models for analysis
and validation [55], [56]. In either case, these models attempt
to replicate the glucoregulatory dynamics of diabetic patients.
However, while the former is concerned with representing
accurate input-output relationships, in the latter category it
is also important that models are structured such that vari-
ables and parameters maintain physiological significance and
produce physiologically viable results at internal states. Thus,
TABLE IV
CHARACTERISTICS OF VARIOUS COMMERCIALLY AVAILABLE INSULIN FORMULATIONS.
Classification Formulation Onset Time Peak Time Duration
Rapid acting Aspart <15 min 30-90 min 3-5 hours
Lispro <15 min 30-90 min 3-5 hours
Glulisine <15 min 30-90 min 3-5 hours
Short acting Regular Human Insulin <1 hour 2-4 hours 4-8 hours
Intermediate acting Human NPH 1-2 hours 4-10 hours 10-18 hours
Long acting (basal) Glargine 1-2 hours - 24 hours
Detemir 1-2 hours - 24 hours
Ultra-long acting (basal) Degludec 30-90 min - 42 hours
models of this second kind, can provide additional insights into
substance and organ interactions, and have become known as
virtual patient models – as they are generally used as simulated
analogs of real patients.
While early models of virtual patients utilized nominal or
average parameter values, obtained from population studies,
their more recent use in developing closed-loop therapy sys-
tems has led to a need for individualized model behaviors
that closely match the severity and mode of dysfunction in
specific patients. Accordingly, while some parameters may still
be estimated by nominal values from population data [58],
others have been identified from measurements on specific
patients. For several models, this method has been used to
generate arrays of virtual patients – called cohorts – that can
be used to represent the interpatient-variability that may exist
within a particular pathophysiology. When used for internal
model type control schemes, the ability or inability to identify
these individualized parameters from readily available data
frequently dictates whether a simulation model is useful for
real-time control. The availability of such data may also
dictate the environments in which it is possible to implement
certain control schemes. This is of particular concern when
adaptation/tuning or online identification is required, as some
diagnostic tools may only be accessible, or practical, in a
clinical setting.
While many physiological models have been studied,
several, such as the Bergman minimal model [59], [60],
UVa/Padova simulator [61], and Cambridge model [62] rep-
resent the overwhelming majority of simulation studies using
virtual patients.
1) Minimal Glucoregulatory Models: While any glucoreg-
ulatory or subsystem model that depicts the essential dynamics
while using the fewest possible states may be considered
minimal [56], [63], the Bergman minimal model (BMM) is
by-far the most well-known and frequently adapted. Despite
simplifications and neglected dynamics, the parameters and
variables in minimal models must both convey clear physio-
logical significance and be readily identified from measurable
clinical data [63]. Notice, this requisite simplicity and iden-
tifiability are often shared with the kinds of models that are
sought in controller synthesis. Hence, in addition to its primary
analytical purpose, the BMM has also been adapted for use
in the implementation of closed-loop blood glucose control
strategies.
To understand the importance of this model, it is interesting
to consider its origin. Initially developed as a means to quan-
tify the insulin sensitivity of individual patients [59], the BMM
was the result of early experiments to identify the structure
of blood glucose-insulin interactions by obtaining frequent
measurements of both plasma glucose and plasma insulin
concentrations through the duration of a 1 hour intravenous
glucose tolerance test (IVGTT) applied following a single bo-
lus injection of glucose. Blood samples were taken first before
injection, to obtain basal levels, and following injection at
specific intervals (i.e., rapidly at first but reducing in frequency
over the hour). The results of these blood tests were fitted
by nonlinear least squares to various pre-established nonlinear
ODE model candidates, which were evaluated according to
the number and physiological meaning of model parameters,
as well as the accuracy of the parameter estimates and each
model’s overall goodness-of-fit. Two of 7 possible models (one
linear, the other nonlinear) passed this initial testing, both of
which included insulin-dependent glucose utilization - 3 of
the models were insulin-independent and were rejected for
their poor prediction of the glucose kinetics. Ultimately, the
nonlinear model was found to reproduce known physiological
responses with higher fidelity. Thus, the BMM was selected
as the 3-compartment nonlinear system of ODEs with 5
parameters shown schematically in Fig. 4 [59]. Notice, this
model has 1 glucose compartment and 2 insulin compartments
(one plasma compartment and one remote compartment).
Since the time of this original model, many adaptations
have been made to account for additional dynamics, such
as the connection of a second glucose compartment, the
addition of glucagon feedback, and the replacement of IVGTT
by oral glucose tolerance testing (OGTT) to obtain a more
physiological measure of insulin sensitivity [64]. However,
even with these augmentations, the BMM must be further
adjusted to be useful for closed-loop control. For example,
one prevalent control-oriented model intended for T1DM
control that utilizes the BMM is detailed in ref. [65]. This
model augments the original BMM with insulin-dependent
glucose dynamics, renal glucose clearance, meal absorption,
external insulin infusion and subcutaneous transport, circadian
variations, and an adjusted hepatic balance.
While many of the equations in this model are linear first-
order ODEs (e.g., all of the insulin and the meal absorption
dynamics), there are several nonlinearities including circa-
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Fig. 4. Original Bergman minimal model of blood glucose/insulin dynamics.
dian variations in insulin sensitivity in the interstitial glucose
compartment and hard nonlinearities in the endogenous blood
glucose production dynamics. Further, any effects caused by
glucagon or physical activity have been excluded. Note, the
original model also includes intravenous routes for insulin and
glucose, which have been omitted above.
Due to its questionable accuracy and remaining complexity,
the BMM is not always the first choice for model-based
closed-loop control. However, it is frequently adapted for
this purpose, and has provided an important clinical tool for
establishing an individual’s level of β-cell function through
the insulin sensitivity index [60], [64], [66]. Like the BMM,
other models used in controller design for closed-loop insulin
therapy generally trade physiological complexity for model
structure, identifiable parameters, and appropriate input-output
behaviors – typically by linearization. This trade-off with tradi-
tional physiological models is – at least partially – responsible
for the increasing role of data-driven models for personalized
control of diabetes [67].
2) UVa/Padova Models and Simulations: Since the time of
the BMM, several detailed models have been developed, or
modified, to analyze the glucoregulatory behavior of diabetic
patients. However, to date, there is only one family of models
that has been approved by the United States Food and Drug
Administration (FDA) as a replacement for pre-clinical trials in
the validation of a closed-loop control design. These are the so-
called UVa/Padova models [68] developed primarily between
collaborators at the University of Virginia in the USA and the
University of Padova in Italy.
In contrast to the simplicity of minimal models, the
UVa/Padova model is a complex and hierarchically organized
model that integrates high and low-level details into submod-
els of organ systems and metabolic pathways, to obtain a
comprehensive, physiological simulation of human patients
[69]. This model, sometimes referred to as a maximal model
due to its maximal level of detail [56], contains over 30
parameters [58] that must be identified to match a specific
patient and is generally too complex to produce desirable
controllers without simplification. Conversely, this complex
model can accurately reproduce many aspects of the glu-
coregulatory dynamics of healthy and diabetic individuals,
which has led to the development of individualized patient
simulation models known as in silico subjects. Using high
quality clinical data, researchers have developed a large collec-
tion of patient models representing numerous individuals from
each of various demographics, enabling studies on the entire
population as well as particular cohorts of interest [61], [68],
[69]. Such detailed high-fidelity modeling is the foundation
for an emerging symbiotic relationship, wherein simulations
are not only useful for analyzing the effects of treatments
on known (patho)physiology, but also for testing hypotheses
regarding the (patho)physiology itself and models thereof
[56].
Presently, a distributed version of the UVa/Padova type
1 diabetes metabolic simulator (T1DMS) for use in MAT-
LAB/Simulink can be obtained by academic and commercial
entities through The Epsilon Group [70]. In addition to its
early capabilities, the current version of the UVa/Padova
simulator includes dynamic models of the bi-hormonal (i.e.,
insulin and glucagon) glucoregulatory dynamics, an improved
patient cohort, and updated depiction of regulatory feedback
during hypoglycemia [61], [70]. As of 2018, researchers from
UVa/Padova have announced further updates to their simula-
tion platform that introduce, among various other extensions
and improvements, a set of time-varying patient models to
account for diurnal variations in patient dynamics associated
with overnight rise in blood glucose (i.e., the dawn phenom-
ena) and patterns of varying insulin sensitivity at morning,
afternoon, and evening meals [71]. While the previous updates
[61] are FDA approved, approval for the more recent time-
varying simulator [71] is still pending at the time of writing
this article.
The development of the UVa/Padova model is well doc-
umented, and interested readers are referred to the relevant
literature for extensive details on the underlying model, in
silico population, recent updates, and application to the val-
idation of control algorithms. Note, despite its complexity,
several closed-loop control algorithms have been designed
using reduced order approximations of these models [55], [72],
[73].
3) Cambridge (Hovorka) Models: Similar to the
UVa/Padova model, the Cambridge model [62], [74], [75] has
frequently been used for in silico validation studies of closed-
loop insulin systems and has its own MATLAB/Simulink
based simulation environment and cohort of 18 clinically
validated virtual subjects [55], [62]. However, unlike the
UVa/Padova simulator, results from this software are not
FDA approved substitutes for pre-clinical trials. While this
may lead to several additional steps prior to clinical studies,
the Cambridge model has significantly fewer mathematical
states and parameters than the UVa/Padova model [58], while
maintaining physiological significance and modeling diurnal
variations, which has allowed some researchers to modify
and adapt it more readily for their specific needs [76].
Despite its complexity, the Cambridge model is frequently
used in internal model or model predictive control schemes
[53], [74] and has been the basis for several clinically tested
investigatory closed-loop devices [75].
4) Alternative and Data-Driven Models: In addition to
the more analytical and physiologically guided virtual patient
models, numerous simplified control-oriented models have
been proposed that attempt to leverage various modeling
paradigms. Of particular interest, the use of linear parameter
varying (LPV) type models [77] has been shown to provide
a simplified means to accurately reproduce the complex time-
varying and nonlinear dynamics of maximal diabetes models.
Using appropriate techniques, reduction of maximal models to
LPV models may provide a superior model-based and control-
oriented approach to blood glucose controller synthesis.
Noting that even the best physiological blood-glucose mod-
els are, at present, phenomenological and difficult to in-
dividualize for optimal real-time control, many researchers
have instead adopted data-driven modeling paradigms such
as autoregressive exogenous (ARX) and autoregressive mov-
ing average exogenous (ARMAX) models. Provided with a
predefined model structure, these techniques utilize online
system identification to obtain and, potentially, update models
to achieve a best approximation of the input-output behaviors
of the glucose-insulin system based on a given performance
index [67]. Like LPV models, it is unlikely that data-driven
models will maintain any detailed physiological information
about a given patient, but instead provide a useful foundation
for implementing established controller synthesis approaches.
5) Models of Therapeutic Agents and CGM Sensors:
Following previous discussions on sensors and treatment ap-
proaches, it is natural that these components will contribute
dynamics to the overall system. Models for CGM sensor
accuracy [78] and insulin formulations and kinetics [79], [80]
have been developed by various investigators. These models
enable simulations that provide a complete picture of blood
glucose control under specific therapy strategies and allow the
investigation of closed-loop systems while taking sensor and
actuator performance limitations into account.
D. Automated Therapy for Diabetes
Attempts to develop fully closed-loop insulin delivery sys-
tems date back more than 50 years [81], and many companies
and academic researchers have contributed significantly in
these developments [82]. While early work focused on sugar
and insulin infusion by intravenous methods, the success
of these systems along with the development of both CSII
pumps and CGM sensors has shifted the modern focus toward
minimally invasive therapies applied via subcutaneous routes
[83]. Within the last 5 years, there has been – and continues to
be – rapid progress toward the commercialization of fully auto-
mated insulin therapy systems [84], [85], frequently referred
to as artificial β-cell, artificial pancreas (AP), or automated
insulin delivery (AID) systems. The primary goal of these
automated therapy devices is to alleviate the burden and risks
associated with multiple daily injections from T1DM patients
and caregivers by reducing diabetes treatment to a combination
of proper lifestyle modifications (perhaps even less stringent
ones once on AP therapy) and device maintenance (to ensure
proper AP function and patient safety). Although most current
work is focused on T1DM, there are parallel efforts to investi-
gate the use of these systems for specific cases such as insulin
dependent T2DM [86], [87], T1DM during pregnancy [88],
[89] (but not yet GDM as far as we are aware), and blood
glucose regulation for patients in intensive care units (ICUs)
[90].
1) Challenges to Automatic Control: While the virtual
patient models discussed previously can reproduce many as-
pects of normal and diabetic blood glucose regulation, there
remain several challenges that prevent these models from fully
predicting the dynamics of real patients in real-time and limit
the accuracy of designs for real-world control performance.
The most notable among these challenges are the blood
glucose disturbances caused by meals and exercise and the
intrapersonal variations – particularly in insulin sensitivity and
glucose production – that may occur within a single patient
over their course of treatment.
While many meal absorption and gastric emptying models
have been proposed to describe how meal contents – generally
carbohydrates – act as sources of exogenous glucose [91],
the timing, duration, and nutritional content of meals and
snacks are generally unknown for patients in an uncontrolled,
or free living, environment. As a substitute for such detailed
information, many current algorithms resort to manual meal
announcement strategies, through which patients or caregivers
can provide nutrition and schedule information to the con-
troller regarding an upcoming meal. However, even with meal
announcement and approximate nutritional content, there may
still be unpredicted digestive variations. Thus, some schemes
– with or without meal announcement – implement meal
detection algorithms that identify when a meal has occurred
and may also estimate carbohydrate content [91]–[95]. At the
current time, very few controllers can provide tight glycemic
control when subjected to unannounced meals as it generally
takes around 70 min after administration for peak insulin
action to occur [95]. This delay in insulin action can provide
a window for hyperglycemia to occur following even a well
identified meal and may result in either hyperglycemia or
hypoglycemia if meal properties are estimated incorrectly.
Like meals, periods of physical activity are known to
disturb the nominal behavior of the blood glucose regulatory
system. However, while meals primarily act by regulating
exogenous glucose, physical activity can simultaneously affect
numerous aspects of a closed-loop therapy system including
physiological requirements [96]–[98], internal bio-mechanical
pressure differentials [98], and CGM accuracy [98]. In fact, it
is well known that different types, intensities, and durations
of physical activity may provoke contrasting physiological
responses (e.g., light aerobic exercise can cause hypoglycemia
and brief stints of intense combined aerobic-anaerobic exercise
can cause prolonged hyperglycemia [85], [96]). Thus, it is not
only important to detect physical activity, but also to obtain
enough data to classify – and perhaps continuously reclassify,
track, or predict – the kinds of activity or exercises a patient
performs. Further complicating this problem, certain kinds of
physical activity can increase the rate of insulin absorption
from the subcutaneous compartment to the blood stream [96],
[98] and the corresponding increase in insulin action can cause
hypoglycemia without any infusion of additional insulin. As
noted previously, insulin does not act immediately and will
not reach peak effectiveness for about an hour; thus, even if
insulin has been regulated correctly for the current level of
physical activity, variations in physical activity can change
the internal utilization of the existing insulin dosage and
affect hypoglycemic excursions that cannot be corrected by
a single-hormone insulin therapy system [96]. To counteract
these effects, many researchers are considering more advanced
control systems that may utilize dual-hormone (i.e., glucagon
and insulin) infusion sets [98], [99] or multiple sensors and
algorithms to detect and characterize physical activity [92],
[96], [100]. Despite these promising developments, there are
currently no accurate models for simulations of exercise in
diabetics [92], [97], and physical activity remains a difficult
challenge for fully automated free-living diabetes therapy.
Additionally, the effects of many other environmental fac-
tors and lifestyle behaviors on localized and body-wide dy-
namics including glucose production, insulin secretion, and
insulin sensitivity are still poorly understood. For example,
recent studies have suggested that insulin sensitivity decreases
significantly in both healthy [101] and diabetic individuals
[102], [103] with reduced duration and quality of sleep.
Further, the effects of circadian phasing, misalignment, and
behaviors (i.e., timing of meals as hours after waking up)
were recently shown to produce 15-20% changes in insulin
sensitivity and β-cell function in healthy adults [104]. To the
authors’ knowledge, similar results have yet to be reported in
diabetics with T1DM or T2DM. Combined with other influ-
ential factors (e.g., sensor and physiological interference from
outside substances, user error in attachment and maintenance,
and electromechanical faults [105]), any model or controller
that has been individualized for a specific patient will almost
certainly be subject to significant time-varying uncertainty,
depending on patient behaviors and operating environment.
While these challenges apply to most diabetics, the exten-
sion of AP systems to T2DM may benefit from updated models
that include compartments and inputs reflecting the action of
noninsulin medications such as metformin, sulfonylureas, and
GLP-1 agonists or additional hormones such as amylin (e.g.,
by the amylin analog pramlintide), which could also benefit
T1DM patients and researchers [106]. Considering the appar-
ent importance of glucagon for avoidance of hypoglycemia
during exercise and the potential benefits of amylin for meal-
time blood glucose regulation, it is not surprising that there
has been recent interest in the development of closed-loop
insulin-glucagon-amylin therapy [107], [108]. However, to the
authors’ knowledge, such complex hormone and combination
therapy models are not yet common in closed-loop diabetes
therapy devices but may provide significant avenues for system
augmentation and a more physiological replication of β-cell
function as the relevant technologies mature.
2) Proportional-Integral-Derivative Control Methods:
Proportional-Integral-Derivative (PID) control is one of the
most versatile and commonly applied methods of control for
both linear and nonlinear systems and has been likened to the
physiological behavior of the pancreatic β-cells [109], [110].
Numerous variations on PID control have been studied in
simulations of T1DM [111], [112] and clinical trials. Most
of the recent clinical studies using PID for closed-loop insulin
delivery are related to the development of the PID-based ex-
ternal physiological insulin delivery (ePID) strategy [1], [110]
including the introduction [1], [113] and refinement [114]
of insulin-feedback (IFB) to a form near the one currently
implemented in the commercially available Medtronic 670G
hybrid closed-loop (HCL) therapy system [115]. In addition
to the PID-based closed-loop control of basal insulin, these
systems provide feedforward control action by meal-time bo-
luses in response to manually entered announced carbohydrate
loads [115]. Systems that implement this kind of manual,
feedforward control are considered hybrid rather than fully
closed-loop.
Another recent algorithm, known as the safety auxiliary
feedback element (SAFE) has been developed that implements
a two-step approach to augment therapy controllers with safety
constraints in order to decouple the problems of achieving
nominal control performance and abiding system limitations
[116]. This auxiliary algorithm runs in a rapidly sampled
(i.e., much faster than the 1 sample/min in the current core
control algorithms) outer-loop that uses sliding mode reference
conditioning to shape the desired insulin infusion profile to
avoid violating safety constraints without affecting the nominal
performance of the main control scheme. The SAFE algorithm
can be used with a variety of controllers and constraints of
known, constant relative degree, and has been used to enhance
the meal-time performance of standard PID [116] and modified
ePID algorithms [117].
In addition to these single-hormone systems, PID has also
been implemented in several dual-hormone (i.e., glucagon
and insulin) systems where it has been used as the control
algorithm for glucagon micro-bolusing (in conjunction with a
separate insulin control algorithm) as well as the control of
both insulin and glucagon [118].
3) Model Predictive Control Methods: For many,
model predictive control (MPC) has become the standard
formulation for insulin delivery algorithms because of its
intuitive treatment of constraints and ease of modification.
Like the many implementations of PID variants, numerous
MPC algorithms have been reported that attempt to leverage
new or existing MPC techniques to improve the compatibility
of these algorithms with the requirements and constraints of
diabetes treatment [82]. Among the more recent developments
in artificial pancreas systems are the extended [119], multiple
model [82], [94], [120], run-to-run tuning [82], [121], zone
[122], [123] and periodic-zone [124], event-triggered [125],
and velocity-weighted & velocity-penalized [126] MPC
algorithms. Each method of MPC attempts to overcome one
or more of the challenges discussed previously including
practical/safety restrictions [127], interpatient variability,
intrapatient variability, and unannounced disturbances such
as meals or exercise. Some of these methods have already
become quite successful and provide important guides for
researchers and engineers seeking to refine diabetes control
strategies.
Safety Considerations: Among the first challenges overcome
by AP algorithms were the restrictions imposed by limitations
on insulin infusion. In principle there are limitations on both
(i) the rate of insulin infusion, for instance due to saturations
in pump displacement and the inability to remove insulin from
the bloodstream once injected, and (ii) the amount of insulin
in a patient’s bloodstream at any given time. Notice, however,
that while these problems are analogous to issues present in
other industries, and general tools like anti-windup are readily
available, the management of insulin is safety critical and
MPC provides a means to design control systems that not only
acknowledge these limitations but anticipate and avoid them
while providing optimal control action. In fact, even predictive
infusion shut-off systems [128], which temporarily halt basal
insulin therapy when continued treatment is predicted to
cause hypoglycemia, without any further feedback capabilities
have been shown to drastically improve system safety by
decreasing the risk of overnight hypoglycemia. However, the
effectiveness of these simple predictive shut-off algorithms
can be diminished if the patient already has significant insulin
in their subcutaneous or plasma compartments. This point is
of particular concern when insulin is infused according to
feedback control laws, which may frequently exceed basal
rates. Thus, many recent systems use insulin action curves to
implement estimates of the patient’s ”insulin-on-board” (IOB)
[129] to account for delayed insulin effects as part of their
predictive algorithm and apply infusion rate limits to avoid
dangerously aggressive profiles when glucose concentrations
are low.
Similar to IOB estimates, another recent and promising
MPC algorithm uses a more accurate estimate of the patient’s
plasma insulin concentration (PIC) to perform online adapta-
tion of dosage constraints for individual patients. This method
has performed well in tests on the UVa/Padova simulator
without using any meal announcement but has not yet gone
to clinical trials [130].
While IOB and PIC estimates can be useful for minimizing
unnecessary control actions, the zone MPC approach attempts
to resolve this issue by replacing the usual desired blood
glucose set-point with a larger region, or zone, of acceptable
concentrations [123]. Thus, the objective of the controller is
better aligned with the normal physiological regulation of
blood glucose to the euglycemic range, rather than a single
specific concentration, and control action is only applied inside
this range if the predictive algorithm anticipates an excursion.
When no excursion is predicted, the basal infusion rate is
maintained, greatly reducing unwanted blood glucose varia-
tions and the risk of insulin induced hypoglycemia. Variations
of the zone MPC approach include periodic zone-MPC control
[124], which accounts for diurnal variations in activity and
reduced hyperglycemic risks overnight, and zone MPC with
adaptive cost functions [126], [131].
Considering the non-negative nature of blood
glucose/insulin concentrations and infusion rates, the
performance limitations of the diabetes control problem,
without glucagon, has been likened to recent results regarding
fundamental trade-offs limiting the achievable response
in linear positive systems [132]. Despite nonlinearities in
the UVa/Padova simulator, this approach may provide a
means to obtain (in the ideal numerical case) the control
signal that would give a near ideal combination of safety
and performance, which has been suggested as a potential
benchmarking tool for simulation studies on AP systems.
One recent MPC variant [126] seeks to achieve this ideal
response by applying (i) a ”velocity-weighted” optimization
wherein the cost of blood glucose deviations is a function of
the rate of change of the measured blood glucose and (ii) a
”velocity-penalization” term in the cost function that penalizes
actions that would allow blood glucose to increase (i.e., have
a positive rate of change) when blood glucose is tending
toward hyperglycemia. In combination, the velocity-weighting
and velocity-penalty MPC scheme acts aggressively against
disturbances by switching on the velocity-penalty at the first
signs of impending hyperglycemia, as evidenced by elevated
blood glucose levels (above some threshold) with a positive
rate of change, while avoiding hypoglycemia due to over
corrections by effectively tapering the control action as the
blood glucose rate of change decreases. Notice, this combined
action is reminiscent of a nonlinear PD control with predictive
capabilities and appears to provide some benefits of both
MPC and PD control strategies.
Model Individualization: Recalling that every patient
affected by type 1 diabetes may respond to treatment
differently, there is no single model or set of model
parameters that can capture every patient’s physiology with
acceptable accuracy. One method to eliminate the uncertainty
(and conservatism) associated with the presence of such
interpatient variability is to generate patient specific models
prior to system deployment or during an initial training
period. To this end, research into individualization of models
[133]–[136] has been an active subject for many years,
and remains an open problem in diabetes control. Despite
this, individualized models alone may not be sufficient to
account for the intrapatient variations discussed previously,
and adaptive control schemes may provide a more robust
answer to both kinds of variability.
Adaptive Control: Unlike the model individualization tech-
niques discussed previously, adaptive online identification
techniques can be used to overcome both interpatient and
intrapatient variability. Clinical uses of online model identi-
fication with MPC date back to the transformative Advanced
Insulin Infusion using a Control Loop (ADICOL) trials of
2004 [74], where model parameters were updated at every
control interval using Bayesian methods over a predetermined
learning window. Other implementations of adaptive control
in MPC include the run-to-run tuning methods in [121], the
cost function updating schemes in [126], [131], and several of
the adaptive schemes discussed in [137].
Furthermore, generalized predictive control (GPC) algo-
rithms [122], [138] have been used successfully in both clinical
and simulation studies. Like MPC, GPC strategies utilize
an internal model to predict future states and determine the
next immediate optimal control signal. However, in GPC, a
simplified model is used for prediction, and this model is
updated (i.e., adapted) at every control interval to minimize the
difference between the predicted and actual responses. Recent
implementations of GPC in diabetes are reported in [137],
[139] using recursive time-series models and in [130] using
recursive predictor-based subspace identification.
4) The Control to Range Method: Similar to the two-step
approach taken by the SAFE algorithm [116], the control-to-
range (CTR) method was proposed as a modular two-element
strategy consisting of (i) a range correction module (RCM)
that operates at a longer (e.g., 1-15 minutes) sampling interval
to maintain blood glucose within a specified target range
and (ii) a safety supervisor module (SSM) that operates at
a much higher sampling rate to predict and prevent dangerous
hypoglycemic excursions [140], [141]. Although this concept
may be applied without regard for the control method used,
the CTR strategy has developed around the use of MPC-based
RCM algorithms [141].
5) Fuzzy-Logic Control Methods: While PID and MPC
have historically dominated the field of diabetes control,
more recently, fuzzy logic controllers [138], [142]–[144] have
been quite successful in generating AP systems that closely
mimic expert clinical decision making in the face of complex
environmental factors and incomplete information.
Among the most prominent fuzzy AP systems used in
clinical trials is the MD-Logic system [142], [145], which
includes information on the patient’s clinical physiology and
therapy guidelines obtained from a set of training data to
provide fully automated individualized care (without meal
announcement) using a combination of control to range and
control to target (standard set-point control) methodologies.
Treatment decisions are made using past, present, and pro-
jected future data (based on trends), forced to abide safety
constraints similar to those discussed previously, and applied
according to a variable basal infusion plus bolus strategy.
Alternatively, another clinically tested fully closed-loop
fuzzy-logic controller (without meal announcement) known as
the dose safety controller (DSC) [143] eliminates the basal
insulin infusion entirely and instead applies a micro-bolus
strategy based on quantized sets of blood glucose level, rate
(i.e., first time derivative of blood glucose), and acceleration
(i.e., second time derivative of blood glucose). To individualize
treatment, each patient is given an initial ”personalization
factor” (PF), which scales the dosage associated with each
level-rate-accelerate combination, and the PF is adjusted to
provide more or less aggressive treatment depending on the
occurrence of hypoglycemic events. More information on
recent updates to the DSC is available online at [146].
6) Run-to-Run Control: Apart from the more well-known
PID, MPC, and fuzzy-logic controllers, a somewhat unique
class of industrial process control techniques known as run-
to-run algorithms [147] have been used for a variety of tasks
in diabetes care. Run-to-run methods utilize a measurement-
based algorithm to improve the effectiveness of a controller
between distinct iterations of a repeated process. For diabetes,
this process may be the 24-hour/3-meal cycle [147]–[149],
in which case the control law is updated before the start
of each day to account for some intrapatient variability and
improve the rejection of blood glucose disturbances due to
meals. Alternatively, similar run-to-run methods have been
used to adjust basal insulin infusion rates in simulated trials
[150] and to improve the accuracy of CGM measurements
based on week-to-week recalibration [151].
7) Alternative Control Methods: While clinical studies have
been dominated by PID, MPC, and Fuzzy-Logic controllers
(with several using CTR), a variety of additional paradigms
have been studied in academic simulations. These methods
include artificial intelligence methods [152], H∞ control [55],
linear parameter varying (LPV) control [77], and sliding mode
control [153]. However, recent clinical studies implementing
these techniques are sparse, if available at all.
E. Outlook for Automated Diabetes Treatment
The insulin-based treatment of type 1 diabetes is currently
in the midst of an international transformation from manual to
automated care. While more complete evidence of the benefits
and burdens of closed-loop therapy will become available as
these systems are adopted, the momentum behind this transi-
tion is bolstered by the significant well-known improvements
in safety and accuracy of closed-loop control over sensor
augmented pump (SAP) therapy and manual multiple daily
insulin injection (MDI) approaches during overnight blood
glucose regulation. Furthermore, both hybrid closed-loop (e.g.,
requiring meal announcement) and fully closed-loop treat-
ments have demonstrated promising additional improvements
in more general simulated and clinical scenarios including
ambulatory and free-living conditions.
Since the initiation of modern closed-loop insulin therapy
clinical trials with the 2004 ADICOL studies [74], there have
been over 100 publications concerning new clinical trials. A
collection of available data regarding recent (2004-2016) clin-
ical trials obtained from several studies [85], [105] is shown in
Fig. 5. This data was cross-referenced against the AP clinical
trial publication database [154] and shows a trend toward the
use of MPC in clinical studies. Among the attractive features
of MPC is its predictive adherence to complicated constraints,
which cannot be offered by PID control or controllers that
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Fig. 5. Clinical AP trials from 2004-2016 grouped according to controller
type.
implement reference conditioning such as the SAFE algorithm.
Despite interest in MPC, the first and only commercially
available hybrid closed-loop system to-date (MiniMed 670G
by Medtronic), released in 2016, uses a PID controller with
insulin feedback (IFB) [155], [156]. While recent studies
regarding the effectiveness and patient reception of this de-
vice are promising [155], [157], many patients expected the
device to have a higher degree of autonomy and found the
system difficult to wear. However, as a larger variety of
commercial systems and fully automated AP systems become
available over the next few years [158], patients will be
able to select between systems to find one that best meets
their needs and expectations. With the widespread adoption
of these technologies will come new safety concerns and
hazards [159] associated with the unfavorable conditions that
may be encountered during continued, long-term, free-living
use. Early action to preemptively address these obstacles may
provide substantial benefits to patient safety, ergonomics, and
perception of closed-loop artificial pancreas systems. Such
actions might include adoption and development of standards
relevant to commercial artificial pancreas systems, such as
IEC 60601-1-10 [13], and familiarization with relevant FDA
guidance (e.g., [160], [161]) and regulatory considerations
arising from public discussions (e.g. [9]).
In addition to commercial systems, opensource solutions to
the treatment of type 1 diabetes, such as the open artificial pan-
creas system (OpenAPS) [162], have been gaining popularity
in recent years. These systems are not regulated by the FDA
and must be designed and constructed by diabetic patients
themselves. While there is a growing repository of source
code and community feedback for interested patients, and the
results of the higher-end patient-driven studies [163], [164]
are impressive, the safety and performance of opensource
medical systems raise serious concerns. Implemented across
a broad and inconsistent scale, these systems are vulnerable
to algorithmic, communication, and electromechanical errors,
which may arise when devices are combined and used in a
manner inconsistent with their design. While some projects,
such as OpenAPS provide a thorough reference guide and code
that incorporates safety limitations, the essence of opensource
implies that there is inevitably little preventing the end-
user from tampering with these constraints and accidentally
creating dangerous devices. This becomes an issue of further
concern when considering the potential for proliferation of
improper designs and the estimated 1/3 of OpenAPS users
who are children operating systems designed by their parents
[165] (however this may not be representative of the larger
opensource community). The availability of simple and reli-
able AP systems may help to significantly reduce the number
of patients who choose to develop their own AP systems, and
in fact the desire for such systems to come-to-market appears
to underlie the goals of OpenAPS. Even with the availability
of name-brand, FDA certified HCL and fully closed-loop
systems, curiosity surrounding their operation – as well as
the desire to replicate and improve it – will undoubtedly drive
continued interest in opensource solutions.
Finally, it is important to keep in mind that poor glycemic
control is a consequence of type 1 diabetes and not the under-
lying cause. As medical practice and technology progress, the
artificial pancreas may be able to grow beyond insulin infusion
and implement more comprehensive and physiologically ap-
propriate therapies. Steps in this direction include the ongoing
work to facilitate bi- and tri-hormonal systems augmented
with glucagon and amylin. Furthermore, there may be benefits
to the investigation of closed-loop therapies that are capable
of affecting both glucose/insulin concentrations and insulin
action (i.e., insulin sensitivity) – perhaps through combination
therapy with non-insulin treatments – to provide personalized
treatment options for the large and diverse population of
diabetics with forms of diabetes other than T1DM. Of course,
economic viability, education for clinicians and new users
of AP devices, and research into a cure for diabetes may
ultimately affect the impact and longevity of automated AP
technology.
IV. AUTOMATED ANESTHESIA
The word anesthesia means the loss of sensation and can
be defined as the lack of response to and recall of noxious
stimuli. The first application of anesthesia was performed by
Crawford Williamson Lang in 1842 using inhaled ether [166].
In clinical settings, anesthesia is induced by the administration
of anesthetic drugs into a patient’s body to achieve localized
or general anesthetic effects. In the latter case, the term
”general anesthesia” refers to a lack of movement across
the whole body while also maintaining an unconscious state.
In general anesthesia, patients may be given two types of
anesthetic drugs: (i) inhaled anesthetics (gases or vapor drugs)
and (ii) intravenous anesthetics (injection drugs). A concise
comparison between these two methods is described well by
Nascu:
”Intravenous medications are given directly into a vein and
are commonly used to induce anesthesia, as induction is usu-
ally smoother and more rapid than that associated with most of
the inhalational agents. Intravenous anesthetics administered
as repeated bolus doses or by continuous infusion may also
Fig. 6. The three functional components of clinical anesthesia: hypnosis,
analgesia and immobility.
be used for maintenance of anesthesia, either alone or in
combination with inhalational agents. An advantage of inhaled
anesthetics is that measuring the difference between inhaled
and exhaled concentrations allows an accurate estimation of
plasma or brain drug uptake· · · ” [167].
Generally, intravenous anesthesia drugs can be categorized
into three different classes based on their physiological effects:
(i) hypnotic drugs, (ii) analgesic drugs, and (iii) neuromuscular
blocking (NMB) drugs. The first kind of anesthetic, called
hypnotics, are used to numb the brain, keeping the patient
unconscious during surgery. Propofol is currently the most
common type of intravenous hypnotic drug due to its fast
redistribution and metabolism inside the body, its lack of
accumulation in tissues [167], and its lower chance of negative
side effects compared to other hypnotic drugs [168]. The
second class of anesthetics, called analgesics, attenuate the
sensation of pain. Currently, opioid analgesics (e.g. remifen-
tanil) are the most common type of analgesic drug. Finally, the
third class of anesthetics, known as NMB drugs, interrupt the
transmission of nerve impulses in the neuromuscular junction
and cause paralysis of the affected skeletal muscles [166].
NMB can be used to facilitate the processes of endotracheal
intubation and mechanical ventilation [169], [170]. As shown
in Fig. 6, each of the 3 classes of drugs used in anesthesia
contribute, respectively, to achieving the 3 main targets of
general anesthesia: (i) hypnosis, or loss of consciousness (due
to hypnotic drugs), (ii) analgesia, or loss of sensitivity to pain
(due to analgesic drugs), and (iii) immobility (due to NMB
drugs).
General anesthesia is performed in 3 phases: (i) induction,
(ii) maintenance, and (iii) emergence. Induction is most critical
phase in anesthesia because all the three types of drugs –
hypnotic, analgesic, and NMB – have to be administered at
high enough doses to induce all 3 main aspects of anesthesia
and allow the anesthesiologist to insert an endotracheal tube
for mechanical ventilation to help the anesthetized patient
breathe (i.e., endotracheal intubation).
Maintenance follows the induction phase. In this phase, the
anesthesiologist balances anesthesia with the use of anesthetics
agents, manages the infusion of intravenous fluids, and regu-
lates the administration of different drugs to maintain hemo-
dynamic stability (i.e., stable blood flow), normal function of
body organs, and adequate depth of hypnosis [171].
Emergence is the last stage of anesthesia and occurs at the
end of surgery when the patient is removed from anesthesia
and brought back to normal conditions as drug administration
is tapered off. The goal of emergence is the full reversal of
neuromuscular blockade and the smooth return of spontaneous
ventilation and reflexes while maintaining the stability of
hemodynamics and other physiological functions. Thus, the
return of consciousness can occur in a safe and comfortable
environment [171].
A. Monitoring
To achieve satisfactory anesthesia, the amount and timing of
drug infusions must be estimated in each phase during surgery.
Several clinical indicators and physiological parameters effect
the anesthesiologist’s estimation. Clinical indicators such as
heart rate, blood pressure, lacrimation, sweating, and papillary
dilatation are monitored during surgery and provide anesthe-
siologists valuable information about the anesthetic adequacy
[172]. However, physiological monitors (i.e., electromyogra-
phy (EMG), electrocardiography (ECG), blood pressure (BP),
electroencephalography (EEG), and oxyhemoglobin saturation
(SpO2)), and quantified indexes such as bispectral index
(BIS), entropy, auditory evoked potential (AEP) and surgical
stress index (SSI) can provide anesthesiologists more accurate
information about a patient’s status [173]. The monitors and
quantified indexes corresponding to several important clinical
signs and physiological parameters are shown in Table V for
reference.
Analyzing the electroencephalogram (EEG) is one of the
most common approaches for precise evaluation of anesthetic
delivery. EEG signals depict the electrical activity in the
cerebral cortex and the characteristics of the EEG waveforms
(i.e., frequency and amplitude) vary by the type of drug
that has been used and the amount of its dosage [174].
There are a number of signal monitoring devices such as the
Bispectral Index (BIS) monitor, Narcotrend monitor, Cerebral
state monitor (CSM), and AEP monitor [175] that measure and
quantify the EEG in order to derive a surrogate measurement
of anesthetic adequacy [176], [177].
Bispectral index (BIS) is the most notable index and is
closely related to the level of consciousness [178]. Measure-
ments of the BIS provide anesthesiologists important infor-
mation during anesthesia, and clinical trials have shown its
potential to increase the patient safety. [179], [180]. The BIS
index is scaled between 0 and 100, where a value of 100
TABLE V
MONITORS AND INDICES FOR CLINICAL SIGNS AND PHYSIOLOGICAL PARAMETERS (ADAPTED FROM [173]).
Clinical signs of inadequate
general anesthesia Monitors Signal processing
Evaluation
indices
Somatic responses
Motor MovementWithdrawal EMG Observation
Power spectral analysis,
BIS,
Entropy
BIS
Entropy
AEP
Consciousness
Nociception
Awareness
Pain
EEG
Subjective experience
Autonomic responses
Breathing Breathing patternchange
Observation Respiration
rate Volume
Coherence Cross-power
Spectrum
CPC(cardiopulmonary coupling)
combined with ECG
Hemodynamic Tachycardia ECG
HRV (heart rate variability)
RRI (R peak interval)
FFT (fast Fourier transform)
LFP (low frequency power)
HFP (high frequency power)
LHR (low/high frequency ratio)
DFA (detrended fluctuation
algorithm, α index)
MSE (multi scale entropy)
CI (complex index)
SSI (surgical stress index)
PVI (pleth variability index)
Volume SPO2 PPGA (plethysmograph amplitude)
Hypertension BP BPV (blood pressure variability)
Sudomotor Sweating Skinconductivity
Papillary dilatation Pupillometry
Lacrimation Observation
Hormonal CatecholaminesCorticosteroids
Blood drawing
and lab analysis
Fig. 7. Patient states corresponding to BIS indices (adapted from [181], [182].
represents the fully conscious state and value of zero depicts an
isoelectric EEG. With increasing concentrations of anesthetic
drugs, the BIS index decreases [181]. Fig. 7 shows the patient
state for ranges of BIS indices along with the corresponding
effects on memory of surgical events. Acceptable BIS scores
for general anesthesia range from 40-60 [178].
Despite its wide-spread use, recent experimental results have
shown that the BIS index is not reliable when patients have
been infused with NMB drugs. In one pivotal study [183],
fully awake subjects were shown to achieve BIS scores below
50 (i.e., corresponding with BIS during general anesthesia)
when dosed with NMB drugs alone. Furthermore, additional
research has suggested that BIS values should be interpreted
with caution when patients are children [184], elderly [185],
have known neurological disorders, or are taking psychoactive
medications [186]. Beyond BIS, it has been noted that, ”the use
of DoA monitors remains a major controversy in anesthesiol-
ogy. Indeed, many factors, such as age, race, gender, low core
body temperature, acid-base imbalances, low blood glucose,
drugs administered to the patient (e.g. neuromuscular blocking
agents), and brain ischaemia, have a significant effect on raw
EEG data. Additionally, DoA monitors are limited by their
calibration range and inter patient variability in dose response
curves...” [186]. These limitations and interactions can degrade
the performance of manual infusion systems and will no-
doubt impose challenges to high-quality closed-loop control of
anesthesia. Recently, patient state index (PSI) algorithm-based
devices have been considered as alternatives to BIS monitors
for their high sensitivity to variations in sedation/hypnosis and
uniform response to various anesthetic agents [186], [187].
Although the PSI devices have some advantages to classical
EEG monitors, including reduced sensitivity to noise, the PSI
index is more sensitive to interpatient variability than BIS
[188] and may be affected by EMG signals [186], [189]. In
general, there remains a need for studies investigating the
effects of drug combinations and EMG signals on sedation
indices. For more detailed information on current challenges
and limitations of monitoring during anesthesia, readers are
referred to the extensive coverage in the literature (e.g., [186]).
B. Modeling
An accurate infusion of anesthesia drugs and continuous
monitoring of brain states during each phase can help de-
crease the frequency and severity of dosage errors, improve
the efficiency of anesthesia, and reduce surgical costs. As
mentioned in Section IV-A, the BIS index is the most com-
mon monitoring metric available for displaying a patient’s
anesthesia level. However, to fully utilize the BIS and other
measures for optimal drug dosing, a mathematical model is
needed that represents all aspects of anesthesia including the
effective physiological parameters and various dynamics (i.e.,
corresponding to the hypnotic, analgesic, and paralytic states).
Various such models exist and can be categorized as single-
input single-output (SISO), multi-input single-output (MISO),
or multi-input multi-output (MIMO) models. In what follows,
anesthesia models from each of these three classes will be
briefly discussed.
1) SISO Model: The pharmacokinetic/pharmacodynamic
(PK/PD) model is a compartmental model that illustrates both
the drug distribution in the human body and its effect on
certain physiological systems. For anesthesia, the pharma-
cokinetics are represented by a linear compartmental model
that defines the concentration of the administered drug in
different parts of human body, while the pharmacodynamics
are represented by a static nonlinear function (i.e., Hill curve)
relating the resulting drug concentration to the measured effect
(e.g., BIS index) [174], [190].
The current PK/PD model is a SISO model with either hyp-
notic drugs (e.g., propofol) or analgesic drugs (e.g., remifen-
tanil) as the input and either patient consciousness or degree
of pain as the output. Such SISO models are used mainly in
anesthesia modeling by control engineers and clinicians. As
shown in Fig. 8, the PK/PD model of anesthesia is a compart-
mental model with three main compartments and one effect-
site compartment where V1 describes the central compartment
including arterial blood, brain, and liver volumes; V2 denotes
the fast peripheral compartment, which has fast dynamics and
contains the well perfused body tissues such as muscles and
viscera; V3 represents the slow peripheral dynamics, which
include the dynamics of poorly perfused body tissues like fat
and bone; and the effect-site compartment is used to account
for the time lag between drug concentration in blood plasma
and its effect [191].
Pharmacokinetic Model: A pharmacokinetic model of a
drug is a mathematical expression relating the concentration
Cp(t) (mg/ml) of the drug in the blood plasma to the infusion
rate of the drug into the central compartment I(t) (mg/min)
[178]. Pharmacokinetic compartmental models are derived by
establishing balance equations for the amount of drug (xi
in mg) distributed in each compartment. Accordingly, the
governing equations for the PK model in Fig. 8 are given
by
x˙1 =
I(t)
V1
− k12x1 − k13x1 − k10x1 + k21x2 + k31x3 (5)
Fig. 8. Patient states corresponding to BIS indices (adapted from [181], [182].
x˙1 = k12x1 − k21x2 (6)
x˙1 = k13x1 − k31x3 (7)
where the constants kij (min−1) indicate the transfer rate of
the drug from the i-th compartment to the j-th compartment;
the constant k10 is the rate at which the drug is metabolized;
and V1 is the volume of the first compartment. These equations
can be written in state space asx˙1x˙2
x˙3
 =
− (k12 + k13 + k10) k21 k31k12 −k21 0
k13 0 −k31

×
x1x2
x3
+
1/V10
0
 I(t) (8)
Cp =
[
1 0 0
] x1x2
x3
 (9)
Then, the transfer function for the PK model from infusion
rate I(t) to concentration Cp(t) = x1(t) is
PK(s) =
Cp(s)
I(s)
=
1
V1
(s+ k21) (s+ k31)
(s+ p1) (s+ p2) (s+ p3)
(10)
where every pi is a function of the constants kij as given by
the conditions p1 + p2 + p3 = k10 + k12 + k13 + k21 + k31p1p2 + p1p3 + p2p3 = (k10 + k12) (k21k31) + k13k21
p1p2p3 = k10k21k31
(11)
The parameters kij are different for each person and can be
calculated as [191]
k10
k12
k21
k31
k13
 =

1
V1
0 0
0 1V1 0
0 0 1V1
0 1V2 0
0 0 1V3

Cl1Cl2
Cl3
 (12)
where Vi and Cli denote, respectively, the volume and clear-
ance rate (i.e., the rate at which the drug is cleared from the
body or removed from the central compartment) of the i-th
compartment. For propofol, the clearance rate and volume
parameters can be obtained asCl1Cl2
Cl3
 =
0.04560
0
0.0264
0
0
−0.0681
0
0
0
−0.024
0

×

weight
height
lbm
age
+
−2.2710.018
0.836
 (13)
V1V2
V3
 =
 0−0.391
0
 [age] +
 4.2739.623
238
 (14)
It should be noted that although the above expressions are
the most commonly used relations for calculating the values
of Vi and Cli, there are alternative, generally more complex,
relations used to calculate these parameters for the infusion of
propofol, such as those developed by [192].
For the infusion of remifentanil, the PK parameters can be
calculated as [193], [194]Cl1Cl2
Cl3
 =
 −0.01620.0301
−0.00113
0.0191
0
0
[age
lbm
]
+
 2.1973.254
0.1212
 (15)
V1V2
V3
 =
−0.0201−0.0811
0
0.072
0.108
0
[age
lbm
]
+
2.0437.124
5.42
 (16)
Note, in (13)-(16), the patient’s height, weight, and age are
given in units of cm, kg, and years, respectively. Furthermore,
the lean body mass (lbm) is calculated differently for male
and female patients and can be obtained as [195][
lbmm
lbmf
]
=
(
m 0
0 f
)(
1.1 −128
1.07 −148
)[ weight(
weight
height
)2] (17)
where m and f are set equal to one and zero, respectively,
for male patients and vice versa for female patients.
Pharmacodynamic Model: Pharmacodynamic models are
used to describe the relationship between the concentration
of a drug and its effect on the body. As shown in Fig.
8, the general PD model has two parts. The first part is a
compartment called the effect-site, introduced by [196], that
represents the lag between drug concentration and its effect.
In the case of anesthesia, since the effect site compartment
is small in comparison with the central compartment, its
effect is assumed to be negligible [197]. In steady-state, the
concentration of the effect-site can be related to the plasma
concentration by
C˙e = x˙e = k1ex1 − ke0xe (18)
where ke0 and k1e are constants and xe is the amount of the
drug in the effect compartment. The rate at which drugs enter
and exit this compartment is assumed to be constant and equal
to ke0 (e.g., k1e = ke0 = 0.456 for propofol) [191]. For the
infusion of remifentanil, ke0 can be calculated as
ke0 = 0.595− 0.007 (age− 40) (19)
Consequently, (19) is often used as
C˙e = ke0 (Cp − Ce) (20)
where Ce is the concentration within the effect-site compart-
ment. Thus, for propofol, the effect site works like a low-pass
filter that relates the plasma propofol concentration (i.e., in the
blood) to the effect-site propofol concentration. The transfer
function describing the relation from the plasma concentration
to the effect-site concentration is given by
Ce(s)
Cp(s)
=
ke0
s+ ke0
(21)
The second part of the PD model, shown as the ”nonlinear
drug/effect relation” in Fig. 8, is often comprised of a sigmoid
Hill equation
E = E0 − Emax C
γ
e
Cγe + EC
γ
50
(22)
where E0 indicates the baseline value (obtained from the
awake state without propofol), which is typically set to 100;
Emax is the maximum effect achievable by the drug infusion;
EC50 denotes the drug concentration at half maximal effect,
which represents the patient’s sensitivity to the drug and
should be measured experimentally; and γ determines slope
of the sigmoid curve (i.e., the receptiveness of the patient to
the drug) [198]. In (22), the value of the effect E is obtained
in terms of the BIS scale. In Table VI, the values of these
parameters are shown for a cohort of 12 representative patients.
These values are among the most frequently used for designing
and simulating anesthesia control systems. Additional data sets
are available in [166].
Although the aforementioned models are used quite fre-
quently, they are in need of some refinements. Among other
issues, the most critical weaknesses of the models presented
thus far include a lack of standard parameters for other
kinds of hypnotic drugs, important neglected factors such as
cardiac output and mode of drug administration (e.g., bolus
or infusion), and unmodeled drug interactions [174]. It is also
worth noting that the commonly used values in Table II are
not representative for a variety of important demographics. In
fact, in the case of infants and adolescents, different PK/PD
models are required, which have been described completely in
[199]–[202].
It should be noted that the SISO models discussed above
incorporate the infusion of hypnotic and analgesic drugs but
do not consider neuromuscular blocking drugs because neu-
romuscular blockade has no effective interactions with anes-
thetic drugs and opioids. In some studies, separate (different)
SISO models are used to represent the dynamics of NMB
[203], [204]. Furthermore, a different PK/PD model structure,
comprised of one central compartment (representing both
TABLE VI
HILL EQUATION CHARACTERISTIC VARIABLES FOR PROPOFOL (ADAPTED FROM [198]).
Patient # Age Height (cm) Weight (kg) Gender EC50 E0 Emax γ
1 40 163 54 F 6.33 98.80 94.10 2.24
2 36 163 50 F 6.76 98.60 86.00 4.29
3 28 164 52 F 8.44 91.20 80.70 4.1
4 50 163 83 F 6.44 95.90 102.00 2.18
5 28 164 60 M 4.93 94.70 85.30 2.46
6 43 163 59 F 12.10 90.20 147.00 2.42
7 37 187 75 M 8.02 92.00 104.00 2.10
8 38 174 80 F 6.56 95.50 76.40 4.12
9 41 170 70 F 6.15 89.20 63.80 6.89
10 37 167 58 F 13.70 83.10 151.00 1.65
11 42 179 78 M 4.82 91.80 77.90 1.85
12 34 172 58 F 4.95 96.20 90.80 1.84
Mean 38 169 65 F 7.42 93.1 96.6 3
blood and organs heavily supplied with blood), one peripheral
compartment (representing the parts of the body with a lower
blood flow), and the effect compartment (representing the PD
model) is presented in the literature [205], [206]. Alternatively,
a second order linear dynamic model is presented for NMB
in [207].
2) MISO Model: While the SISO model in Section IV-B1
can be used separately for both hypnotic and analgesic drugs,
it is not capable of fully representing the combined ad-
ministration and effects of these drugs. As a work around,
some studies have used parallel SISO models of each drug
to obtain a simple MISO model. In this arrangement, the
WAVCNS index used by the NeuroSense NS-701 (NeuroWave
Systems, Cleveland Heights, USA) monitor appears to be a
more suitable measurement index than BIS for measuring the
anesthesia level because it is obtained through a linear time-
invariant relation that does not cause an additional delay in the
closed-loop system [208], [209]. The interaction of propofol
and remifentanil is described in [210] as
E (vp, vr) =
(vp + vr + αvpvr)
γ
(vp + vr + αvpvr)
γ
+ 1
(23)
where νp = (cpe)/(EC
p
50), νr = (c
r
e)/(EC
r
50), and the
parameter α (identified from clinical data by [210]) determines
the degree of interaction between propofol and remifentanil.
This interaction is clasified as synergistic if α > 0; additive if
α = 0; and antagonistic if α < 0. The parameters ECp50 and
ECr50 are the propofol and remifentanil concentrations at half
maximal effect.
As an alternative to using the PK/PD models of propofol and
remifentanil in parallel, a new MISO Weiner model called the
parameter parsimonious model (PPM) has recently been intro-
duced by [211]. In this model, the effect-site concentrations
of propofol and remifentanil (i.e., cpe and c
r
e, respectively) due
to their infusion rates (i.e., up and ur, respectively) are given
in the Lapalce domain as
Cpe (s) =
k1k2k3α
3
(k1α+ s) (k2α+ s) (k3α+ s)
up (s) (24)
Cre (s) =
l1l2l3η
3
(l1η + s) (l2η + s) (l3η + s)
ur (s) (25)
where α and η are dependent on patient parameters and do not
have any physiological meaning. The parameters ki and lj are
dimensionless constants that were obtained from clinical data
by [212] as k1 = 10 , k2 = 9, k3 = 1, l1 = 3, l2 = 2, and
l3 = 1. The corresponding BIS value z(t) is approximated by
[211] as
z (t) =
97.7
1 + U(t)
γ (26)
where
U (t) = µ
Cpe
ECp50
+
Cre
ECr50
(27)
In these equations, the parameters µ and γ do not have any
physiological meaning and are dependent on each patient. This
model can be expressed in state space as [213]
x˙ (t) = Ax (t) +Bu (t) (28)[
Cpe (t)
Cre (t)
]
=
[
0
0
0
0
1
0
0
0
0
0
0
1
]
x (t) (29)
U (t) = Cx (t) (30)
where
A =
[
Ap 0
0 Ar
]
, B =
[
Bp 0
0 Br
]
(31)
Ap =
−k1α 0 0k2α −k2α 0
0 k3α −k3α
 ,
Ar =
−l1η 0 0l2η −l2η 0
0 l3η −l3η
 (32)
Bp =
k1α0
0
 , Br =
l1η0
0
 (33)
C =
[
0 0
µ
ECp50
0 0 1ECr50
]
(34)
The common values for α, γ, µ and η are identified by
[214] and are given in Table VII.
Although the PPM model is not entirely physiological,
it is better suited to model-based control than the general
PK/PD model because it has fewer parameters that need to be
TABLE VII
COMMON PPM PARAMETER VALUES (ADAPTED FROM [213]).
Patient # Gender Age Height (cm) Weight (kg) α η γ µ
1 F 56 160 88 0.0667 0.3989 1.7695 2.1502
2 F 48 158 52 0.0874 0.0670 0.9365 4.7014
3 F 51 165 55 0.0693 0.0482 2.8186 1.1700
4 F 56 160 65 0.0590 0.0425 2.7594 1.4077
5 F 64 146 60 0.0489 0.1269 1.5627 1.4171
6 F 59 159 110 0.0677 0.3373 4.1247 1.1444
7 F 29 163 59 0.0737 0.2793 0.7812 0.8986
8 F 45 155 58 0.0860 0.0212 0.9780 1.4203
9 F 51 163 55 0.0701 0.2837 1.0956 1.2164
10 F 32 172 56 0.1041 0.1038 1.2165 1.9085
11 F 68 160 64 0.0343 3.5768 1.7097 2.5451
12 F 50 161 68 0.0467 0.1254 2.4877 1.4884
13 F 68 158 113 0.0687 4.5413 1.0859 2.3951
14 F 70 161 78 0.0774 0.0397 1.4038 1.5460
15 F 73 160 75 0.0995 0.0377 1.3706 2.0485
16 F 34 162 57 0.0929 0.1205 4.5194 1.5565
17 F 43 155 62 0.0811 0.1033 2.1978 2.0338
18 F 66 155 74 0.1336 0.2307 1.0849 1.2061
identified [213]. However, both the PK/PD and PPM models
have been used in many controller design studies. Some im-
portant factors for choosing between these models include the
availability of measurement devices, the type of desired control
structure, the types of drugs being administered, and the costs
associated with the overall design and implementation. In
the following sections, some recent studies that utilize these
models will be discussed.
3) MIMO Model: While the previous models have a single
measurable output (e.g., BIS or WAVCNS), there are several
other variables that can be considered as additional system
outputs. Two MIMO models have been reported prevalently
in the literature, both of which take the dosage of hypnotic
and analgesic drugs as inputs but differ in the quantities used
as outputs. When considering MIMO systems with m inputs
and n outputs, we can define m × n transfer functions that
describe the effects of each input on each output.
The first of these MIMO models [215], which is used less
frequently in the literature, includes some clinical metrics like
heart rate and blood pressure as system outputs. By assuming
the analgesic drugs have negligible effects on the BIS value
[216] and considering depth of hypnosis (DoH) and blood
pressure as the system outputs, this model is given by
xB = e
−τBs KB
TBs+ 1
UB (s) (35)
xP = e
−τP s KP
TP s+ 1
UP (s) (36)
yB = 100− fB (xB (t)) + dB (37)
yP = 100− fP (xP (t)) + dP (38)
where indexes B and P denote hypnotic and analgesic drugs,
respectively; τB and τP are initial time delays; KB and KP
are defined as drug sensitivities; TB and TP are time-constants
representing the response speed of the patient; fB and fP are
defined in [217] as nonlinear sensitivity functions; dB and dP
are external disturbances; UB(s) and UP (s) are the Laplace
Fig. 9. MIMO Wiener model for the depth of anesthesia (adapted from [218]).
transforms of drug infusion rates; xB and xP are the effect-
site concentrations of the anesthetic drugs; and yB and yP are
the DoH and mean blood pressure, respectively. According to
(27), this representation consists of four (i.e., 2× 2) different
transfer functions, which are reported in [215].
The second common MIMO model, depicted in Fig. 9,
defines the infusion rates of propofol (i.e., the hypnotic drug)
and remifentanil (i.e., the analgesic drug) as the inputs, and
the patient’s depth of hypnosis and degree of pain are used
as the system outputs. Thus, the depth of hypnosis and
degree of pain are interpreted from BIS and state entropy
(SE) measurements, which consequently may be considered
alternative model outputs. The state-space of this model is
similar to the MISO model of (24)-(33); the main difference
between these models is the output matrix, which is described
as [218]
y =
[
y1
y2
]
=

y01
1+
(
Cre
ECr50
+ρ1
C
p
e
EC
p
50
)γ1
y02
1+
(
Cre
ECr50
+ρ2
C
p
e
EC
p
50
)γ2
 (39)
where y1 denotes the BIS value; y2 denotes the SE value;
y01 and y02 are equal to 97.7 and 91, respectively; and ρ1, ρ2,
γ1 and γ2 are parameters that are estimated by clinicians.
TABLE VIII
INCIDENCE OF AWARENESS DURING SURGERY (ADAPTED FROM [221]).
Year Sample size Awareness (percent of patients)
1960 656 1.2
1971 120 1.6
1973 200 1.5
1975 490 0.8
1990 1000 0.2
1997-1998 11785 0.15
1993-2000 10811 0.11
2001-2002 19575 0.13
2003 7826 0.18
2004 1238 0.9
2005 150000 0.07
C. Automation in Anesthesia
In 2010, 48.3 million surgical operations were performed
in the U.S. [219]. Many of these surgeries require gen-
eral anesthesia, yet ensuring optimal and on-time infusion
of anesthetic drugs remains an important challenge that is
complicated by the unique physiology of each patient and
numerous known and unknown environmental factors. Further
complicating this problem, patients’ anesthetic requirements
are known to change during surgery in both predictable and
unpredictable ways, and once administered, anesthetics cannot
be removed. Poor regulation of anesthetics, such as too little
hypnotic or too much analgesic, can result in complications
including anesthesia awareness (i.e., unintended consciousness
during surgery), pain during surgery, prolonged emergence
period, and increased risks of other side effects [220]. As an
example of the regularity of these complications, Table VIII
shows data collected on the incidence of anesthesia awareness
over the last half-century.
Although the statistics above show a near steady improve-
ment, there are still many faults occurring during anesthesia
administration which may be avoidable by the development
of an automated anesthesia system that improves the admin-
istration of anesthetics and mitigates the hazards of system
faults. In fact, besides a reduced risk of surgical complications,
the use of an automatic control system may provide signifi-
cant additional benefits such as a reduction in the cognitive
workload of the anesthesiologist (who must be present to
supervise any automated system), a decreased volume of drugs
administered (which implies a faster and better recovery time
of the patient in the post-operative phase), and a more robust
performance with fewer over- and under-dosing episodes and
better rejection of surgical disturbances. Of course, the main
goal is increased safety and comfort for the patient [222].
The advantages of automatic anesthesia systems over manual
anesthesia have recently been validated by experimental results
[223].
Any automated anesthesia system will likely include two
main phases: first, the desired depth of anesthesia (DoA) (i.e.
desired BIS index) must be reached, and second the DoA
needs to be maintained by the application of various anesthetic
drugs. During the first phase, the system should calculate the
sufficient drug dose and regulate its infusion to move from
the initial BIS value E0 of the patient during the induction
phase to a final desired BIS value. Note, the determination
of a desired DoA means setting final values for all the three
types of anesthesia (hypnotic, analgesic, and neuromuscular
blocking drugs). However, to date, most closed-loop studies
have been focused only on achieving the depth of hypnosis
(DoH), which is the most important type of anesthesia, while
the analgesic and neuromuscular blocking drugs must still be
infused manually by clinicians.
During the second phase, the system should infuse the
drugs continuously while monitoring the aforementioned phys-
iological parameters and clinical signs and also rejecting
disturbances that occur during the maintenance phase. The
main goal during this phase is to maintain the patients at
the final BIS value throughout the surgery until anesthesia is
stopped during the emergence phase.
Control applications in general anesthesia began receiving
attention several decades ago [224], [225] from both control
engineers and clinicians. Throughout this period, a variety
of methods have been proposed with varying degrees of
automation. As illustrated in Fig. 10, most systems can be
categorized as manual, open-loop feed-forward, or closed-loop
controllers based on the approach used to calculate the drug
infusion rates in general anesthesia.
Manual systems (i.e., without automation), shown in Fig.
10a, are the current standard practice. In these systems, an
anesthesiologist first sets the final value of the DoA or DoH
and then monitors the anesthetic state of the patient and
regulates the drug dosages accordingly [226]. The success
of this method is highly dependent on the expertise of the
individual anesthesiologist and is not reliable in some critical
situations (e.g., irregular events during surgery).
In 2003, a large step toward achieving fully automated
anesthesia was taken with the introduction of target controlled
infusion (TCI) systems [227]. The Diprifusor system was
the earliest commercial TCI pump for propofol [228] and
since its introduction several other TCI systems have become
available from various manufacturers. In fact, developments
and modifications to TCI systems has made them a standard
among infusion systems for the administration of opioids,
propofol, and other anesthetics in clinical practice [228].
Considering our categorization, TCI systems operate as open-
loop feed-forward controllers, shown in Fig. 10b, which rely
on both an anesthesiologist to assess the patient’s state and
the output of a PK/PD model to estimate an exact drug dosage
and infusion time. In practice, the anesthesiologist sets a target
drug concentration, and the TCI system determines an infusion
rate and sends this value to the infusion pump. Although
these systems are used in many countries and have some
advantages over manual anesthesia systems, the success of TCI
still depends heavily on the expertise of the anesthesiologist
and does not have its own means of identifying the patient’s
current needs when tuning the infusion rate. Since TCI lacks
real-time feedback, its performance depends on the accuracy
of the patient model and is susceptible to disturbances caused
by surgical stimulation and hypnotic-opioid synergy (i.e., the
Fig. 10. Schematic overview of drug dosage calculation and infusion used in
clinical anesthesia with (a) manual control, (b) open-loop feedforward control,
also known as TCI, and (c) closed-loop control system (adapted from [226])
combined effects of these drugs) [226].
Closed-loop controllers are the most advanced of the 3
categories and consider the individual patient’s physiological
parameters in addition to the clinical metrics (used by anes-
thesiologists in manual and TCI approaches) in the process
of calculating infusion rates. As mentioned in Section IV-A,
such physiological parameters may already be available as
the measured output of advanced monitors that record and
display values including the patient’s EMG, EEG, ECG, and
BIS. In this case, feedback control is used instead of an
anesthesiologist to frequently adjust the infusion profile or
target concentration in closed-loop controllers; however, anes-
thesiologists are still needed to set the desired DoA or DoH
and supervise the patient’s state via clinical metrics. The result
is a reduction in the anesthesiologist’s workload, potentially
helping to avoid problems associated with distractions and
fatigue, as well as increased safety for the patient due to
continuous monitoring, the possibility of lower administered
drug dosages with a faster postoperative recovery, and a
reduction in the occurrence of drug-induced side effects [229].
For these reasons, fully automated systems may have the
potential to one-day outperform manual infusion dosing [230],
[231].
Two different approaches for implementing closed-loop
controllers in anesthesia are shown in Fig. 11. The first, in Fig.
11a, is based on a scheme that directly identifies the anesthetic
Fig. 11. Two commonly used closed-loop control architectures in anesthesia
drug delivery with (a) direct control of the infusion rate, and (b) cascaded
control of TCI system (adapted from [226])
infusion rates and sends control signals directly to the infusion
pump (e.g. [232]). The second, in Fig. 11b, continuously
adjusts the target value for a downstream TCI system, which in
turn continuously sets the rate of the infusion pump (e.g. [233],
[234]). The second method can be considered a special case
of the first, and so the first (direct) approach is less restrictive
and may be preferable for control design as the TCI dynamics
can be replaced with any effective algorithm.
Generally, automation in anesthesia consists of three main
components: a patient model, a measurement system (i.e.,
sensors or monitors), and a controller. Each of these com-
ponents can have significant effects on the performance of
the other components and the overall system. For example,
as mathematical models become more accurate and include
more detail on variables and effective parameters, controllers
can be designed to provide higher quality drug infusion.
Furthermore, as measurement devices become more accu-
rate, individualized physiological model parameters can be
identified more accurately and controllers will have access
to a higher quality and quantity of relevant information via
feedback and observation - ultimately resulting in improved
drug infusion. Note, the quality of monitoring directly effects
the controller performance in implementation.
While Sections IV-A and IV-B have focused on model-
ing and monitoring, controller design is among the largest
remaining challenges to automated anesthesia, and we will
now review several prominent strategies. Many scientists and
control engineers have explored various control approaches
such as PID, MPC, fuzzy-logic, adaptive, and neural networks
as well as hybridizations of these controllers to design and
produce automatic anesthesia infusion systems for clinical use
following the general structure in Fig. 12. Some comprehen-
sive reviews on controller designs can be found in [174],
[235]–[238].
While the majority of recent publications in the physio-
logical closed-loop control of anesthesia are related to the
use of intravenous anesthesia, several closed-loop studies have
specifically considered the application of inhalational anesthe-
sia [239]–[241]. One benefit of the inhalational approach to
anesthesia is that it may be considered safer than intravenous
anesthesia because end tidal gas measurements are available
Fig. 12. Closed-loop control for drug administration in anesthesia (taken from
[178]) with permission pending.
to monitor the drug concentration within the brain and the
vessel rich group (VRG) at steady state. However, these
sensors provide a poor approximation of the VRG concen-
tration during common dynamic situations such as initial
uptake and emergence [242]. Thus, some researchers have
developed mathematical models to represent these dynamics
(e.g., for purposes of concentration estimation) with the aim
of investigating, by simulation and clinical studies, the closed-
loop control of inhalational anesthesia using model predictive
control [243]–[245]. For detailed information on modeling
and closed-loop control of inhalational anesthesia, interested
readers are referred to the extensive coverage in the literature
(e.g., [246]).
1) Challenges to Automated Anesthesia: During the design
and simulation phases of the controller development, there are
several important constraints that must be taken into account.
First, each drug has a maximum effective dosage, which means
higher doses will not have any greater effect on the patient.
Second, because the control signal defines the infusion rate, it
cannot have a negative value (i.e., the drug cannot be extracted
once infused) and must further be within the operating range
of available infusion pumps. Third, excessive doses infused
over a short time can shock the human body and may harm
organ systems [247]; this can be avoided by maintaining lower
infusion rates. The selection of proper drug infusion rates is
determined as a trade-off between the side-effects of rapid
infusion and the desire to reach the required BIS value within a
certain time-frame. In current surgical operations, the optimal
time-frame has been reported as around 15 minutes [167],
while shorter periods are frequently obtained in simulation
studies found in the literature (e.g., 4-8 minutes in [222]).
Lastly, the designed controller must work in the presence of
both interpatient and intrapatient variability.
In addition to these systematic constraints, different sources
of disturbances and noise – such as poor signal quality and
surgical stimulations – should be considered in the system
modeling and controller design activities. Of these distur-
bances, surgical stimulations are among the most challenging
to manage and are a subject of current investigations by both
clinicians and control engineers. As an example of how these
stimulations may arise, Fig. 13 shows a typical timeline of
the variations in BIS index, caused by surgical stimulations,
during the time-course of an archetypal surgical procedure.
In this figure, stimulus A shows the arousal due to laryn-
goscopy/intubation; B represents surgical incision followed by
Fig. 13. A standard surgical stimulation profile (adapted from [179]).
a period of no surgical stimulation (e.g., waiting for laboratory
results); C represents an abrupt stimulus after a period of low
level stimulation; D represents the onset of continuous normal
surgical stimulation; E, F, and G simulate high amplitude
short-term stimulations within the surgical period; and H
simulates the withdrawal of stimulation during the closing
period [179].
As discussed in Section IV-A, there is currently a need
for more accurate, reliable, and robust sensing techniques that
provide real-time monitoring of a patient’s depth of anesthesia
(DoA) without reliance on demographic characteristics or
undesirable interference from EMG signals, NMB drugs, or
interactions with other substances (e.g., opioids affect AEP
measurements [248]). The present limitations to these sensing
technologies may represent a fundamental barrier to accurate
closed-loop control. Consider, for instance, the recent results
regarding NMB drugs and BIS [183], which have a direct
consequence on closed-loop control. According to this study,
an anesthetic PCLC device can – under the right circumstances
– achieve the desired BIS value without actually reaching
the desired DoA (e.g., potentially resulting in anesthesia
awareness). Even in the case where DoA is generally well
represented by the sensing paradigm, automated anesthesia
remains challenged by sensor noise, measurement error, and
sensing delays.
In the next sections, the most common controllers used
in closed-loop control of anesthesia will be discussed, and
the recent developments and remaining challenges to each
approach are presented.
2) Proportional-Integral-Derivative Control: Proportional-
integral-derivative (PID) control is one of the most used
control approaches in industrial applications due to its simple
mathematics, well-known gain tuning methods, and broad
capabilities. Several successful clinical and simulation studies
of automated anesthesia have been performed using PID based
controllers over the past two decades such as [227], [249]–
[254]. The simulated and experimental results of these studies
have generally indicated that PID control may have some
utility in the closed-loop control of anesthesia. One of the
most common PID controllers used anesthesia is given by the
Laplace domain transfer function [222]
U (s)
E (s)
= kp
(
1 +
1
sTi
+ Tds
)
1
(Tfs+ 1)
2 (40)
where U(s) and E(s) are, respectively, the Laplace domain
control and error signals; kp is the proportional gain; Ti is
the integral time-constant; Td is the derivative time-constant;
and Tf is the time-constant of a second-order filter used to
attenuate measurement noise.
In the relevant works, the proposed PID controllers have
been shown to track desired anesthesia levels (e.g., desired
BIS values); however, anesthetists and control engineers agree
that this simple PID algorithm suffers from major deficiencies
because it is not a robust and adaptive controller and does
not perform well in the presence of noise and physiological
variability. As a result, simple PID gives poor disturbance
rejection, unwanted oscillations in the BIS response, and
can suffer from windup of the integral control term during
the induction phase. Therefore, recent studies are trying to
address these problems to achieve comparable performance
to other more advanced controllers. For instance, in [255] it
is shown that the low-pass filter, included in (40), reduces
the sensitivity of the derivative term to random changes.
Furthermore, introducing zero reference weight for the propor-
tional and derivative control terms (i.e. no reference input for
proportional and derivative parts) results in better disturbance
rejection and avoids unwanted oscillation in the BIS response
[256]. Other investigations have shown benefits from applying
a tracking time-constant as the geometric mean of the integral
and derivative time-constants of the PID controller [257] and
introducing reference shaping (i.e. the desired BIS index is
changed from a step input to a specialized profile) [170]
and integrator anti-windup [258] to prevent integrator windup
during the induction phase. Some alternative approaches that
have also been shown to improve the PID controller perfor-
mance include using an event-based control scheme, which
decreases the variations of controller signal and optimally
cancels the noise and disturbances, and using an inversion-
based methodology, which increases patient safety by reducing
BIS overshoot and producing a smoother drug infusion rate
[259]. From the clinical point of view, event-based control
is similar to manual infusion and is more transparent to
anesthesiologists because they can easily monitor the drug
infusion profile [229].
Additional challenges to controller design stem from the
presence of nonlinearities (i.e., a Hill equation) in the anes-
thesia dynamics. One common approach to handle this nonlin-
earity is to linearize (22) around the nominal operating point
(e.g., a BIS value of 50) in the maintenance phase [260], [261].
This linearization converts (22) into a constant coefficient km
given by
km = −BIS0γ
4EC50
(41)
where BIS0 is the nominal operating point in the maintenance
phase. However, this approach is not feasible in the induction
phase because the lack of a well-defined nominal operating
point causes a large overshoot in the response due to the
integral term of the controller. Recently, a new approach has
been proposed, which is applicable to both induction and
maintenance phases. This approach uses a linearizing filter in
series with the inverse of the nonlinear part of the Hill function
[256], [262].
Since the structure of PID controllers is generally well-
defined, the selection or tuning of controller gains is very
important. This task is challenging in closed-loop control of
anesthesia, since the gains should be tuned according to the
physiological parameters of each patient [263], [264]. While
trial and error is common in tuning PID controllers [261],
optimization methods, such as genetic algorithms [257], [265],
[266] aimed at minimizing the integrated error, can increase
the performance significantly [258], [267]. Nevertheless, the
physiological parameters of patients vary based on age, weight,
disease, and type of surgery being performed, and presently
the available patient data is limited and does not adequately
depict the physiological parameters of all patients. Therefore,
online identification of patient parameters can be useful for
improving the controller performance [268]. Additional studies
have shown that the use of gain scheduling techniques may
also be beneficial. In this case, the gains should be tuned
different for different phases of surgery. During the induction
phase, the gains are tuned to follow the set-point with a
reasonable setting-time and low overshoot. Then, during the
maintenance phase, the gains should be tuned for disturbance
rejection. Therefore, when DoH or BIS levels reach the target
value and have stabilized around the set-point for an adequate
time interval (i.e., signaling the end of induction phase) the
controller parameters should be switched to those tuned for
the maintenance phase [222].
Another important point is that PID controllers are fre-
quently used in different configurations (e.g., PD or PI only)
for different dynamics. However, recent studies have proved
that all three parts are necessary in anesthesia control. For
example, in [269] the derivative part is eliminated to prevent
noise amplification, but the performance in the induction phase
and disturbance rejection in maintenance phase were less
satisfactory for this PI controller than for the PID case, which
had a shorter settling-time and less undershoot in the BIS
response.
3) Model Predictive Control: Model predictive control
(MPC) is a robust and optimal control technique used to handle
systems with constraints while optimizing the controller action
and predicting system outputs for robustness against noise and
disturbances. The applicability of MPC and related strategies
(e.g., generalized predictive control (GPC)) to medical systems
– especially in closed-loop control of anesthesia – has been
verified by both simulation and clinical results [270]–[273].
The outstanding features of this controller have recently en-
couraged control engineers to further develop MPC controllers
to address the complex and nonlinear behavior of closed-loop
anesthesia control.
One caveat with standard MPC is the complexity of the
computations used to solve the online optimization problem,
which prevents its use in real-time anesthesia control. This
limitation can be overcome by using a multi-parametric MPC
(mp-MPC) technique, which reduces the complexity of the
computations by solving an offline optimization problem on
an analytical function instead of numerical solutions [274],
[275]. Further, to improve rejection of BIS noise and surgical
disturbances, MPC has been implemented in combination
with advanced state estimation techniques such as Kalman
filtering and moving horizon estimation (MHE). Simulation
results show that the MHE method has better accuracy and
reduced overshoot compared to Kalman filtering [276], [277].
Likewise, studies have also shown that the addition of event-
based input and state output correction features to MPC can
increase its robustness against noise and decrease the amount
of anesthetic drugs administered [278], [279].
Another strong point of MPC is its ability to handle intrap-
atient and interpatient variability through online estimation of
pharmacodynamic parameters [245], [280], estimation of the
slope of the linearized Hill equation at each time-step [281],
[282], and the use of offset-free and state output correction
strategies [278], [283].
Piecewise linear PK/PD models can be used to address the
problem of nonlinearities in the PD model, which represent
one of the main challenges in closed-loop control of anes-
thesia. This technique defines several linear parts in the hill
function to achieve a more accurate linear approximation of
this function [198], [283]. Likewise, multiplying the inverse
of the Hill function
Ce (t) =WC50
(
E0 −BIS (t)
Emax − E0 +BIS (t)
) 1
γ
(42)
into the input command and the feedback signal is a common
approach to cancel the nonlinear part of the anesthesia system
[284]. Other techniques such as linear model predictive control
(LMPC) [285]. switching the control strategy of mp-MPC to
apply bolus treatments in critical BIS indexes [277], extended
prediction self-adapting control (EPSAC) [198], and online
identification of time delays [280] can improve the perfor-
mance of closed-loop anesthesia as evidenced by reduced
settling-times (i.e., obtaining a faster response), decreased
overshoot, and the elimination of unwanted oscillations from
the BIS response.
4) Adaptive Control: Adaptive controllers are frequently
applied to systems with variable or unknown parameters, and
implement algorithms that retune or restructure the effective
controller during operation (i.e., online) [286], [287]. As
mentioned, the PK/PD model of anesthesia is subjected to
large (possibly time varying) uncertainties and its coefficients
are different from patient to patient. Thus, adaptive controllers
show promise for estimating parameters of the PK/PD model
and improving the regulation of anesthesia.
Adaptive controllers that adjust their control action by
directly changing controller gains (rather than an internal
model) are known as direct adaptive controllers. One such
method of direct adaptive control is to implement an adap-
tive proportional-integral-derivative control algorithm, which
allows adaptive control of anesthesia without directly using
the PK/PD model [288]. However, in practice, this con-
troller produced undesirable oscillations and its performance
was considered unacceptable. Some studies have also shown
improvements to the performance of these controllers by
considering the nonlinear uncertainties in the PK model and
designing nonlinear adaptive controllers [289]. Additionally,
neural networks have been used to improve the performance
of nonlinear adaptive controllers for dynamic systems with
complicated uncertainties [290]. In these controllers, states of
the physical system remain in nonnegative orthant of the state
space [291]. The effectiveness of this type of controller has
been investigated by using several experiments and clinical
evaluation [292].
As an alternative to direct adaptive control, indirect adaptive
control uses parameter updating laws to identify unknown
parameters in an internal reference model and thereby retune
the effective controller gains. Several methods are used to
obtain such control laws [234], [293], [294], and studies
have shown that variations between simulated and real-world
control performance can be attenuated by using a minimally
parameterized model with an online identification strategy
(e.g., an Extended Kalman Filter) to design adaptive nonlinear
controllers [212].
Other types of adaptive feedback controllers have also been
designed for anesthesia, including model reference adaptive
controller (MRAC). However, MRAC controllers based on
standard models do not show significant improvements in per-
formance over non-adoptive techniques. Alternatively, MRACs
may also be implemented using fractional order models [295],
and the results of studies using fractional order models have
confirmed the effectiveness and robustness of fractional order
model reference adaptive control (FOMRAC), which can also
compensate for the time delays in the anesthesia system [296].
Similarly, L1-adaptive methods can achieve faster adaptation
than MRAC [297] and have demonstrated good performance
and interpatient robustness [298]. In addition, system iden-
tification methods can reduce the order of patient models
while also improving performance over standard L1-adaptive
control [299]. Furthermore, L1-adaptive controllers can be
used to ensure the safe switching between human-in-the-loop
and automated close-loop modes of operation [300].
5) Fuzzy-Logic Control: Since the compartmental models
of anesthesia are not exact representations of the human body
and are subject to variability in system parameters, closed-
loop control of anesthesia can benefit from fuzzy modeling
and control. In fact, fuzzy-logic has been applied successfully
to all three compartments of anesthesia (i.e., hypnosis [301]–
[304], analgesia [305]–[307] and immobility [308], [309]).
Some comprehensive reviews can be found in [173], [310].
The main benefit of using fuzzy-logic for anesthesia is its
ability to express patient models by clustering real patient data
without any knowledge of the underlying physiology. Most
fuzzy anesthesia systems use regular (i.e., type-1) fuzzy sets,
which have members that take crisp values in [0 1]; however,
some systems use type-2 fuzzy sets where the membership
values of each element are in another fuzzy set in [0 1] [311].
Finding the best membership function (MF) for such fuzzy
sets in [0 1] is one of the main problems with using fuzzy
models. To this end, genetic and neural network algorithms
are commonly used to improve performance and optimize the
type-2 fuzzy sets’ parameters (e.g., footprint of uncertainty
(FOU), centroid, and scaling factors) [312]–[315].
To develop fuzzy control laws, sets of rules are collected
according to the expert opinions of anesthesiologists regarding
the best corrective actions to take under sets of circumstances.
Then, these sets of rules are implemented with an aim to create
a closed-loop system that mimics their expertise at manual
infusion [316]. It should be mentioned that even with these
rules, fuzzy-logic controllers have not demonstrated suitable
performance without also being combined with genetic and
neural network algorithms. Using these algorithms improves
the fuzzy controller by allowing adaptation in the presence of
interpatient and intrapatient variability [317].
Frequently, fuzzy-logic controllers are changed to so-called
self-organized fuzzy-logic controllers that are capable of
adapting to changes in the system [318]. However, these
controllers are known to cause steady-state error when used
with bolus type therapy. To overcome this, simple fuzzy-
logic can be used during bolus treatment and the controller
can be switched to the self-organized fuzzy-logic type once
the system is operating near the desired set-point [302]. As
mentioned before, genetic algorithm can then be used for
optimizing the fuzzy-logic model [310].
The majority of the fuzzy-logic controllers are based on
the type-1 set which cannot handle model uncertainties, and
controllers that are based on type-1 sets suffer from steady-
state error in the fuzzy estimation of the desired set-points.
However, these problems can be handled by changing to type-
2 fuzzy sets [319]. Moreover, fuzzy neural network controllers
can be used to handle uncertainties in anesthesia [320]–[323],
but this approach has limited effects on the type-1 fuzzy
sets. So, type-2 fuzzy neural network controllers are used
to solve this problem [324]. Furthermore, controllers based
on type-2 fuzzy-logic sets can be improved by switching
to a self-organized strategy, resulting in self-organized type-
2 fuzzy-logic controllers, which can compensate for control
uncertainties [2]. By adding genetic algorithms to find the best
membership function for the self-organized type-2 fuzzy-logic
controller, better results can be obtained in noisy (i.e., real)
environments at the cost of increased error in the noise-free
environment [311].
As mentioned, type-2 self-organizing fuzzy-logic controllers
are effective. However, signal noise and dynamic uncertainties
– such as changes in the PD and PK systems – can degrade
controller performance [325]. In most cases, merging fuzzy-
logic controllers with other control schemes can ameliorate the
final results. For instance, hybridization of fuzzy-logic with
MPC can help to predict the effects of uncertainties in system
[326], [327].
D. Outlook for Automated Anesthesia
As mentioned previously, there are four different types
of controllers that are commonly used in the closed-loop
control of anesthesia: proportional-integral-derivative, model
predictive, adaptive, and fuzzy-logic controllers. Besides these
controllers, strategies such as observer-controllers [213], ro-
bust and robust deadbeat controllers [220], [263], [328], non-
linear H-infinity controllers [329], non-overshooting tracking
controller [330], sliding mode controllers [331], [332], and
other types of nonlinear controllers [333] have been studied for
use in anesthesia. Some of these studies have employed per-
formance metrics such as settling-time, overshoot, undershoot,
lowest observed BIS value (BIS-NADIR), performance error
(PE), median performance error (MDPE), median absolute
performance error (MDAPE), total variation (TV), integrated
absolute error (IAE), and WOBBLE (an index of response
variations over time) to compare their results and controller
effectiveness to other control strategies in attempts to demon-
strate advantages over other schemes and find the most suitable
class of controllers for anesthesia [272], [334]–[336].
From a control systems perspective, most of the controllers
discussed have shown adequate performance. Additionally,
some important studies recently have been done regarding
safety systems for closed-loop of anesthesia [337], [338].
However, due to the safety critical nature of anesthesia and
consequently restrictive laws, from the clinical point of view,
no controller has been completely acceptable for use in a fully
closed-loop anesthesia system yet. In fact, none of the four
controllers discussed are by themselves able to overcome the
complex problem of anesthesia due to the presence of intra-
and inter-patient variability, surgical disturbances, and nonlin-
ear dynamics. As recent papers indicate [326], [327], [339],
combinations of these controllers – optimized to leverage their
individual strengths – show promise for improving the per-
formance of closed-loop anesthesia and achieving acceptable
simulation results.
The development of automated anesthesia systems capable
of achieving broad international regulatory approval may bene-
fit from improved physiological models designed to include the
interactions of more organ systems, physiological parameters,
and clinical signs for an appropriately diverse cohort of sub-
jects and surgical scenarios. If such a model further included
all three modes of anesthesia, simulation results might provide
a higher degree of confidence in the safety and performance
of control algorithms at an early stage. Concurrently, it is also
apparent that there is a need for control relevant anesthesia
models with reduced model complexity while maintaining the
ability to capture intra- and inter-patient variability. The de-
velopment of such models will require collaboration between
clinicians, anesthesiologists, mathematicians, and control en-
gineers.
Furthermore, automated anesthesia would also benefit from
developments in clinical monitoring aimed at achieving sig-
nificant reductions in measurement noise and time-delays as
well as the realization of methods to quantify specific aspects
of anesthesia. To this end, quantification of the depth of
anesthesia may provide interesting opportunities to investigate
the use of sensor fusion to develop reliable metrics based
on multimodal (and perhaps redundant) monitoring. Since
the nonlinear pharmacodynamics of anesthesia are difficult
to model, the development of methods to measure the drug
concentration in the effect compartment may also help to
remove the need for the corresponding nonlinear model equa-
tions and introduce a new set-point to complement or replace
BIS values. Again considering the shortcomings of current
monitoring technologies, it appears that fully autonomous
(unsupervised) anesthesia should not be employed, until a
reliable real-time measure of DoA is discovered. Under further
consideration of the rapidly developing pharmacological and
medical fields, the challenge presented by possible as-of-yet
unknown drug interactions and patient variability (with respect
to DoA metrics) may, in general, provide sufficient cause to opt
for moderated levels of automation (LOA) in PCLC anesthesia
devices (i.e., always incorporating the anesthesiologist in a
supervisory role).
Moving forward, research into the optimal combination of
control strategies has the potential to introduce controllers that
are feasible for real-world use. Of course, any commercial
controller for anesthesia should be able to perform properly in
the presence of infusion limitations (e.g., the amount, rate, and
frequency of drug infusion), intra- and inter-patient variability,
noise, disturbances, and nonlinearities, while also meeting
standards for safety and regulatory approval.
V. DISCUSSION AND FUTURE OF PHYSIOLOGICAL
CLOSED-LOOP CONTROL
Considering the historical and current investigations in
PCLCs, including the artificial pancreas and automated anes-
thesia, there are several common issues that must be han-
dled when implementing control on physiological systems.
Chief among these are the ever-present intra- and inter-patient
variations that come with age, health, genetics, hormones,
medications, physical activity, and a variety of other inherent
and environmental factors. The combination of this variability,
its many pathways, and the complex nature of physiology leads
to challenges in both controller design and system validation.
The presence of interpatient variability, or differences in the
responses observed between different patients, introduces the
need for controller robustness and a large collection of high
quality clinical data for validation. However, even with a
large collection of data, there remains a question of patient
dynamics that are not represented by the data or have not yet
been encountered. Furthermore, the presence of intrapatient
variability, or changes to the responses observed within a
single patient, introduce time-varying dynamics which may
further introduce either parametric or structural uncertainties.
The overwhelming potential for plant-model mismatch has
led to a wide acceptance of adaptive techniques in PCLC
formulations, used in combination with robust or predictive
control strategies.
Another key issue in PCLC is the presence of strict con-
straints on therapy, which often allow only positive valued
control actions (e.g., substances like propofol and insulin-
analogs cannot be removed once injected) and limit both
the rates and amplitudes of applied treatments and estimated
physiological states. Of course, one of the most important
methods in designing systems that combine these requirements
with adaptation and robustness are those based on predic-
tive control approaches. Then, the application of prediction
to physiological control places a significant burden on the
observers and estimators to provide reliable approximations
of constrained physiological quantities. While there are ar-
guments for other control methodologies, predictive control
methods have been gaining momentum in PCLC and are
likely to continue as mathematical models of physiological
and pharmaceutical systems develop.
Changing our focus to a different portion of the feedback
loop, the ability to obtain accurate and on-time measurements
is of utmost importance for both safety and performance.
Thus, the development and availability of improved sensing
technologies will, in part, dictate the success of PCLCs.
Currently, direct access to many measurable physiological
states requires highly invasive approaches, which often can-
not be justified for long-term or ambulatory use. Thus, less
accurate, and possibly delayed, measurements are being used
as surrogates, for instance in diabetes, which may impose
significant performance limitations. While weighing the risks
of trade-offs in measurement quality vs. invasiveness provides
a short-term solution in some fields, there is an immediate
need for improved and miniaturized measurement techniques,
perhaps by translation from other fields, that provide rapid and
accurate results without jeopardizing patient comfort or health.
If we consider the case of long-term PCLC solutions, worn
by patients for months or years or in free-living conditions,
other issues arise as well. For instance, many electrochemical
sensors limited lifespans. This case is evident in the CGM
systems used for artificial pancreas systems, which last at
most around 2 weeks prior to replacement and may provide
degraded performance at the early and late stages of use.
Additional concerns with long-term use include irritation or
infections at attachment sites. Further, the unrestricted envi-
ronments presented by free-living conditions may lead to cases
of unforeseen sensor failures or errors, similar to the effects
of physical activity on subcutaneous glucose measurements,
wherein physiological redistribution of glucose during exercise
may bias subcutaneous measurements. On the contrary, the
FDA recently approved the first fully implantable glucose
sensor, which has a 90-day lifespan and operates on fluorescent
sensing technology [340]; new technologies such as this may
provide solutions to some of the classical issues with GCM.
Finally, the potential for interactions between multiple drugs
or between drugs and sensing elements, as in the case of
Tylenol and some CGM systems, should be considered, to the
extent possible, in future investigations. As PCLCs mature and
data becomes available, it may be possible to implement such
interactions within the in-silico models used for validation.
These models have already vastly improved the rate of con-
troller development in the field of diabetes control and been
successful in many other areas as well [341]. The addition of
PK-PD models for multiple drugs and known drug interactions
within these models may help identify risks or possible failure
modes in ambulatory use.
Relaxing, slightly, the definition of physiological control to
include systems with a primary goal of achieving a target
drug concentration (rather than physiological effect), there
is additional growing interest in applying control theory to
regulate the concentration of pharmaceuticals within certain
organs/tissues in the human body [285], [342]. While dosage
control alone may reduce the effects of variability in pharma-
cokinetics and indirectly improve regulation of physiological
variables, it is also possible that such dosage control could be
incorporated as a target in future MIMO physiological control
systems. Of particular note in this adjacent field are the recent
success of feedback control using electrochemical-aptamer-
based (E-AB) sensors [343]) and the development of long-
acting bioresponsive pharmaceuticals [344], which implement
a form of analog closed-loop control whereby tailored drugs
remain inactive in the body until stimulated by biological
feedback conditions.
Modern interest in physiological and pharmaceutical control
have helped bring about the development of a new field
distinguished as mathematical pharmacology [345], which
focuses specifically on modeling the pharmacokinetic and
pharmacodynamic properties of substances. Future work in
this field is likely to provide direct support to advanced
automation in medical practice in the form of new and refined
pharmacological models as well as insights into the classes
of models [346] (and therefore control paradigms) that are
well matched to a given drug-dosage or physiological control
problem. Furthermore, the integration of mathematical phar-
macology with systems physiology has the potential to entrust
modeling and control design activities with the respective
experts in each area and alleviate the present bottleneck
wherein control design and validation is faced with significant
uncertainty in part due to the complexity of physiological and
pharmaceutical interactions.
Clearly, the development of mathematical models for control
design [347] and evaluation remain important areas of research
in physiological closed-loop control. Further, while we have
mentioned that some methods of control do not require an
explicit mathematical model, these methods may be difficult to
evaluate in a computational setting, and considering the risks
involved with physiological systems the immediate future of
such methods in PCLC – especially with regard to regulatory
approval – is unclear [9]. Of course, the effectiveness of
model-based control is itself subject to the appropriateness of
the model(s) used for controller design [347], and a recent
review [348] has shown that many published methods fall
short of completely demonstrating their suitability to the
proposed use (e.g., controller design, closed-loop performance
evaluation, hardware-in-the-loop testing) in PCLC devices.
This problem is exacerbated by the limited data available
to many researchers as well as the extraordinary range of
potential disturbances, interactions, and variability that affect
physiological systems. Ongoing work in the area of credibility
assessment for computational patient models [348], [349]
and the recently published V&V 40 standard for ”assessing
credibility of computational modeling” for medical devices
[350] from the American Society of Mechanical Engineers
(ASME) seek to provide guidance for establishing model
credibility based on the specific context of use (COU), model
influence in decision making (e.g., selection of infusion rate),
and consequences of suboptimal decisions [348]. Within this
framework, researchers are able to qualify their modeling and
control results with appropriate rigor and can establish the
credibility of models and techniques as new areas of PCLC
emerge. This framework may also have significant value for
justifying comparisons between control and safety strategies.
With all of these ongoing efforts and the promise of
future developments, it seems that the broad introduction of
commercially available PCLCs is now imminent, and the
coming decades will likely see many breakthroughs in this
regard. Thus, pertinent discussions on appropriate regulatory
policy are underway [9], and similar conversations are being
held with regard to ethical implementation of automation in
medicine [351], [352]. The continuation of these discussions
and refinement of regulatory and ethical guidelines is essential
to the future of PCLCs, for establishing both methods of safe
practice and guidelines for design, and also for well-informed
selection and use of novel medical instruments by hospitals
and physicians.
VI. CONCLUSION
In the years to come, closed-loop medical devices, artificial
intelligence, and networked medical instruments [353] will be-
gin to emerge along existing medical robotics [354], [355]; and
physiological closed-loop control systems will become visible
within the clinical, home-care, and ambulatory environments.
Ultimately, it is possible that many of these devices will be
linked to an electronic health network, which could maintain
critical patient data or even allow physicians to monitor and
adjust treatment goals remotely.
The integration of feedback control and artificial intel-
ligence in medical systems has the potential to improve
adherence to prescribed treatment regimens and protocols,
rapidly adapt to new or changing therapy strategies, provide
access to treatment in remote areas, optimize the utilization
of available resources in scenarios with supply limitations,
and increase the capacity of the individual clinician in disaster
response and humanitarian crises. The consistency of treatment
and availability of data that follows automation may be a
useful tool for evaluating the performance of certain clinical
practices, validating new treatment options, creating innovative
therapies, and enabling the wide-spread availability of per-
sonalized medicine. These achievements, and others yet to be
conceived, will not be obtained without navigating substantial
challenges but appear within reach during the 21st century.
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